=> d his

```
(FILE 'HCAPLUS' ENTERED AT 11:15:41 ON 10 NOV 2004)
                DEL HIS
     FILE 'REGISTRY' ENTERED AT 11:15:45 ON 10 NOV 2004
                E AMMONIUM HYDROXIDE/CN
L1
              1 S E3
                E AMMONIUM CARBONATE/CN
L2
              1 S E3
              1 S 463-79-6
L3
           7072 S 463-79-6/CRN
L4
            158 S L4 AND H3N
L5
             81 S 1336-21-6/CRN
L6
L7
              3 S L4 AND L6
              6 S L5 AND 2/NC NOT MNS/CI
L8
              5 S L8 NOT 15N
L9
L10
              5 S L2, L9
     FILE 'HCAPLUS' ENTERED AT 11:24:15 ON 10 NOV 2004
L11
          14300 S L1
          86001 S NH4OH OR NH4 OH OR (NH4 OR AMMONI?) () (MONOHYDRATE OR MONO HYD
L12
L13
          86918 S L11, L12
L14
           7775 S L10
           9914 S NH42CO3 OR NH4 2CO3
L15
           6714 S (AMMONI? OR NH4 OR DIAMMONI? OR MONOAMMONI? OR BIS AMMONI?)()
L16
            581 S AMMONI? HYDROGEN CARBONATE OR ACID AMMONI? CARBONATE OR CARBO
L17
           2586 S AMMONI?()(BICARBONATE OR BI CARBONATE)
L18
             45 S NH4() (BICARBONATE OR BI CARBONATE)
L19
            144 S "E 503" OR "E503" OR AMMONI? HYDROGENCARBONATE
L20
            139 S CARBONIC ACID (L) ?AMMONI? SALT
L21
L22
          17301 S L14-L21
           2565 S L13 AND L22
L23
L24
             14 S L23 AND ?SACCHARIDE?
L25
              1 S L24 AND OLIGONUCL?
              1 S US20040096948/PN OR (US2003-643502# OR WO2003-US33888 OR US2
L26
                E HUANG Y/AU
L27
            762 S E3,E20
                E HUANG YUN/AU
             73 S E3
L28
              8 S E24
L29
             11 S E121
L30
                E MECHREF Y/AU
L31
             48 S E3-E6
                E NOVOTNY M/AU
            465 S E3, E8, E26, E27
L32
                SEL RN L26
     FILE 'REGISTRY' ENTERED AT 11:38:19 ON 10 NOV 2004
              2 S E1-E2
L33
     FILE 'HCAPLUS' ENTERED AT 11:38:33 ON 10 NOV 2004
                E OLIGOSACCHARIDE/CT
L34
           2878 S E71
            286 S E72, E74
L35
                E E5+ALL
          34817 S E3-E5, E18, E38-E41, E46-E49, E51-E53, E55, E57, E64
L36
L37
         169197 S E3+NT
L38
          19474 S L36-L37 (L) PREP+NT/RL
L39
          19725 S L34, L35, L38
            290 S L39 AND GLYCOPROTEIN?/CW
L40
                E GLYCOPROTEIN/CT
          79879 S E102+OLD
L41
```

```
79859 S E102
L42
                E E102+ALL
L43
          42456 S E3-E5
          85033 S GLYCOPROTEIN#/CW
L44
            290 S L39 AND L41-L44
L45
            436 S L39 AND GLYCOPROTEIN
L46
            436 S L40, L45, L46
L47
            942 S GLYCOPROTEIN#/CW (L) RACT+NT/RL
L48
          14313 S GLYCOPROTEIN#/CW (L) PROC+NT/RL
L49
             68 S L48, L49 AND L39
L50
             68 S L48, L49 AND L47
L51
             68 S L50, L51
L52
              5 S L52 AND CLEAV?
L53
              2 S L52 AND L13, L22
L54
              8 S L52 AND (NH4? OR NH3? OR ?AMMONI?)
L55
L56
              8 S L54, L55
              7 S L56 NOT SUPERPARAMAGNET?/TI
L57
              4 S L27-L32 AND L52
L58
             29 S L27-L32 AND CARBOHYDRATE?/SC, SX
L59
             12 S L25, L26, L53, L54, L57, L58
L60
L61
             26 S L59 NOT L60
                SEL DN AN 4
              1 S L61 AND E1-E3
L62
             13 S L60,L62
L63
              3 S L27-L32 AND L11-L22
L64
             34 S L27-L32 AND ?AMMONI?
L65
              8 S L27-L32 AND (NH4? OR NH3?)
L66
             39 S L64-L66
L67
                E BETA ELIMINATION/CT
                E "B-ELIMINATION"/CT
                E E4+ALL
L68
            716 S E2
             55 S E4
L69
L70
              5 S L52 AND L68, L69
L71
             15 S L63, L70
              3 S L67 AND L68,L69
L72
              3 S L67 AND BETA (L) ELIMINAT?
L73
L74
             15 S L71-L73
              7 S L52 AND BETA(L)ELIMINAT?
L75
             17 S L74, L75
L76
             17 S L76 AND L11-L33, L34-L76
L77
             17 S L77 AND (NH4? OR NH3? OR ?AMMONI? OR ?SACCHARIDE? OR CARBOHYD
L78
L79
             10 S L78 AND CARBOHYDRAT?/SC,SX
              7 S L78 NOT L79
L80
```

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:06:45 ON 10 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE LAST UPDATED: 9 Nov 2004 (20041109/ED)

reagent)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d 179 all hitstr tot
     ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
L79
     2004:414519 HCAPLUS
AN
DN
     140:407068
     Entered STN: 21 May 2004
ED
ΤI
     Glycoprotein cleavage protocol for
     oligosaccharide analysis
IN
     Huang, Yunping; Mechref, Yehia S.; Novotny, Milos
PA
     USA
SO
     U.S. Pat. Appl. Publ., 13 pp.
     CODEN: USXXCO
DT
     Patent
LA
     English
IC
     ICM C12P019-04
     ICS C08B037-00
NCL
     435101000; 536123000; 536018700
CC
     33-4 (Carbohydrates)
FAN.CNT 1
                                               APPLICATION NO.
                                   DATE
     PATENT NO.
                           KIND
                                                                          DATE
                                                                           -----
                           ----
                                    -----
                                                 _____
                                              US 2003-643502
                                                                           20030819 <--
ΡI
     US 2004096948
                            A1
                                    20040520
                                    20040603 WO 2003-US33888
     WO 2004045501
                            A2
                                                                           20031024 <--
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
              LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,
              BY, KG, KZ, MD
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
              CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
              GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-426921P
                        P
                                    20021115
                                              <--
     US 2003-643502
                            Α
                                    20030819 <--
CLASS
 PATENT NO.
               CLASS PATENT FAMILY CLASSIFICATION CODES
                  ----
                          _____
 US 2004096948 ICM
                          C12P019-04
                  ICS
                          C08B037-00
                  NCL
                           435101000; 536123000; 536018700
AB
     An NH4+-based \beta -elimination
     cleavage of linked oligosaccharides from
     glycoproteins is described. The method enables the isolation of
     glycoprotein-derived oligosaccharides having a reducing
     end which enables subsequent derivatization for chromatog. and/or mass
     spectral anal. The described glycoprotein cleavage
     protocol enables structural investigations using low microgram quantities
     of glycoproteins.
     glycoprotein cleavage oligosaccharide prodn
ST
IT
     Fetuins
       Glycoproteins
     RL: BCP (Biochemical process); RCT (Reactant); BIOL
      (Biological study); PROC (Process); RACT (Reactant or
```

```
(glycoprotein cleavage protocol for
        oligosaccharide anal.)
IT
     Oligosaccharides, preparation
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic
     preparation); BIOL (Biological study); PREP (Preparation)
        (glycoprotein cleavage protocol for
        oligosaccharide anal.)
ΙT
     Elimination reaction
        (β -; glycoprotein cleavage protocol
        for oligosaccharide anal.)
     88-68-6, 2-Aminobenzamide
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (derivatization of reducing glycans with 2-aminobenzamide)
IT
     9026-00-0
     RL: BCP (Biochemical process); RCT (Reactant); BIOL (Biological study);
     PROC (Process); RACT (Reactant or reagent)
        (glycoprotein cleavage protocol for
        oligosaccharide anal.)
     88-68-6, 2-Aminobenzamide
IT
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (derivatization of reducing glycans with 2-aminobenzamide)
RN
     88-68-6 HCAPLUS
     Benzamide, 2-amino- (9CI) (CA INDEX NAME)
         NH2
       NH<sub>2</sub>
TΨ
     9026-00-0
     RL: BCP (Biochemical process); RCT (Reactant); BIOL (Biological study);
     PROC (Process); RACT (Reactant or reagent)
        (glycoprotein cleavage protocol for
        oligosaccharide anal.)
     9026-00-0 HCAPLUS
RN
     Esterase, cholesterol (9CI) (CA INDEX NAME)
CN
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
L79
AN
     2004:414514 HCAPLUS
DN -
     140:407067
ED
     Entered STN: 21 May 2004
     Method of preparation of oligosaccharides
ΤI
     Huang, Yunping; Konse, Tomonori; Mechref, Yehia S.;
IN
     Novotny, Milos V.
PA
     USA
     U.S. Pat. Appl. Publ., 10 pp.
SO
     CODEN: USXXCO
DΤ
     Patent
LA
     English
     ICM C12P021-06
IC
     ICS C12P019-04; C08B037-00
NCL 435068100; 435101000; 536053000
CC
     33-4 (Carbohydrates)
FAN.CNT 1
                                            APPLICATION NO.
     PATENT NO.
                         KIND
                                DATE .
```

```
US 2003-664462
                                                                      20030919
     US 2004096933
                           A1
                                 20040520
PΙ
                                             WO 2003-US34088
                                                                     20031024
     WO 2004045502
                          A2
                                 20040603
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-426861P
                           Р
                                 20021115
                           Α
                                 20030919
     US 2003-664462
CLASS
                 CLASS
                         PATENT FAMILY CLASSIFICATION CODES
 PATENT NO.
                         _____
                 _ - - - -
                         C12P021-06
US 2004096933
                 ICM
                         C12P019-04; C08B037-00
                 ICS
                 NCL
                         435068100; 435101000; 536053000
     The invention provides a method of cleaving an O-linked
AΒ
     oligosaccharide from a glycoprotein. The method
     comprises the steps of contacting a composition comprising a
     glycoprotein, wherein the glycoprotein comprises
     O-linked oligosaccharides, with a solution comprising a BH3-
     NH3 complex to form a mixture comprising the glycoprotein
     and the BH3-NH3 complex, incubating the mixture for a period of
     time sufficient to cleave the linked oligosaccharides
     from the glycoprotein, and forming a mixture comprising
     oligosaccharide alditol products and deglycosylated protein
     byproducts.
ST
     oligosaccharide prodn glycoprotein cleavage
     borane ammonia
     Glycoproteins
IT
     Mucins
     RL: BCP (Biochemical process); RCT (Reactant); BIOL
     (Biological study); PROC (Process); RACT (Reactant or
     reagent)
        (preparation of oligosaccharides by cleaving an O-linked
        oligosaccharide from a glycoprotein)
     Oligosaccharides, preparation
IT
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic
     preparation); BIOL (Biological study); PREP (Preparation)
        (preparation of oligosaccharides by cleaving an O-linked
        oligosaccharide from a glycoprotein)
                   75472-69-4P
                                  166982-47-4P
                                                  169227-20-7P
IT
     70268-06-3P
     RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); BIOL
     (Biological study); PREP (Preparation)
        (preparation of oligosaccharides by cleaving an O-linked
        oligosaccharide from a glycoprotein)
                                            13283-31-3D, Borane,
     7664-41-7D, Ammonia, borane complex
IT
     ammonia complex
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (preparation of oligosaccharides by cleaving an O-linked
        oligosaccharide from a glycoprotein)
     ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
L79
     2002:469613 HCAPLUS
AN
DN
     137:259501
ED
     Entered STN: 24 Jun 2002
     Matrix-assisted laser desorption/ionization mass spectrometry compatible .
ΤI
```

```
beta.-elimination of O-linked oligosaccharides
     Huang, Yunping; Konse, Tomonori; Mechref, Yehia;
ΑU
     Novotny, Milos V.
     Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA
CS
     Rapid Communications in Mass Spectrometry (2002), 16(12), 1199-1204
SO
     CODEN: RCMSEF; ISSN: 0951-4198
PΒ
     John Wiley & Sons Ltd.
DT
     Journal
     English
LA
     9-5 (Biochemical Methods)
CC
     Section cross-reference(s): 33
     A new \beta -elimination procedure has been introduced
AB
     to cleave O-linked oligosaccharides from low- to sub-microgram
     amts. of glycoproteins prior to anal. by mass spectrometry. Borane-
     ammonia complex in aqueous ammonia is used as a cleaving
     solution alternative to the sodium borohydride/sodium hydroxide medium
     conventionally used in \beta -elimination. The
     procedure results in min. sample purification, leading to minimal sample loss
     and consequently an overall enhancement in sensitivity. It was applied
     successfully in the anal. of bovine fetuin and submaxillary mucin, as well
     as to a complex bile-salt-stimulated lipase glycoprotein isolated from
     human milk.
ST
     MALDI MS O linked oligosaccharide
IT
     Oligosaccharides, analysis
     RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical
     study); BIOL (Biological study)
        (O-linked; matrix-assisted laser desorption/ionization mass
        spectrometry compatible \beta -elimination of
        O-linked oligosaccharides)
IT
     Milk
        (human; matrix-assisted laser desorption/ionization mass spectrometry
        compatible \beta -elimination of O-linked
        oligosaccharides)
     Elimination reaction
IT
     Human
        (matrix-assisted laser desorption/ionization mass spectrometry
        compatible \beta -elimination of O-linked
        oligosaccharides)
IT
     Fetuins
       Glycoproteins
     RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical
     study); BIOL (Biological study)
        (matrix-assisted laser desorption/ionization mass spectrometry
        compatible \beta -elimination of O-linked
        oligosaccharides)
     Bile salts
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
        (matrix-assisted laser desorption/ionization mass spectrometry
        compatible \beta -elimination of O-linked
        oligosaccharides)
     Laser ionization mass spectrometry
        (photodesorption, matrix-assisted; matrix-assisted laser
        desorption/ionization mass spectrometry compatible \beta -
        elimination of O-linked oligosaccharides)
     Laser desorption mass spectrometry
IT
        (photoionization, matrix-assisted; matrix-assisted laser
        desorption/ionization mass spectrometry compatible \beta -
        elimination of O-linked oligosaccharides)
IT
     9004-54-0, Dextrans, analysis
     RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical
```

study); BIOL (Biological study)

(matrix-assisted laser desorption/ionization mass spectrometry compatible β -elimination of O-linked oligosaccharides)

- oligosaccharides) THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 37 RE(1) Andrews, G; Tetrahedron Lett 1980, V21, P693 HCAPLUS (2) Baba, T; Biochemistry 1991, V30, P500 HCAPLUS (3) Carlson, D; J Biol Chem 1968, V243, P616 HCAPLUS (4) Chai, W; Eur J Biochem 1992, V203, P257 HCAPLUS (5) Chai, W; Eur J Biochem 1992, V207, P973 HCAPLUS (6) Davies, M; J Chromatogr 1993, V646, P317 HCAPLUS (7) D'Arcy, S; Biochem J 1989, V260, P389 HCAPLUS (8) Easton, R; J Biol Chem 2000, V275, P21928 HCAPLUS (9) Hansson, L; J Biol Chem 1993, V268, P26692 HCAPLUS (10) Hokke, C; Eur J Biochem 1994, V221, P491 HCAPLUS (11) Hounsell, E; Glycoconjugate J 1996, V13, P19 HCAPLUS (12) Huang, Y; Anal Chem 2001, V73, P6063 HCAPLUS (13) Huang, Y; Rapid Commun Mass Spectrom 2000, V14, P1233 HCAPLUS (14) Huang, Y; in preparation (15) Hudlicky, M; Reduction in Organic Chemistry 2nd edn 1996, V188, P19 (16) Landberg, E; Arch Biochem Biophys 1997, V344, P94 HCAPLUS (17) Lloyd, K; J Biol Chem 1996, V271, P33325 HCAPLUS
 (18) Mechref, Y; Anal Chem 1998, V70, P455 HCAPLUS
 (19) Mechref, Y; Biochem Biophys Res Commun 1999, V255, P451 HCAPLUS
 (20) Mechref, Y; Chem Rev in press
 (21) Mechref, Y; J Am Soc Mass Spectrom 1998, V9, P1293 HCAPLUS
 (22) Mechref, Y; in preparation
 (23) Morelle W: Carbobydr Pes 1998, V306, P435 HCAPLUS (23) Morelle, W; Carbohydr Res 1998, V306, P435 HCAPLUS (24) Ogata, S; Anal Biochem 1982, V119, P351 HCAPLUS (25) Patel, T; Biochemistry 1993, V32, P679 HCAPLUS (26) Rademaker, G; Anal Biochem 1998, V257, P149 HCAPLUS (27) Ryschkewitsch, G; J Am Chem Soc 1960, V82, P3290 HCAPLUS (28) Savage, A; Biochem J 1991, V279, P95 HCAPLUS (29) Savage, A; Eur J Biochem 1990, V192, P427 HCAPLUS (30) Savage, A; Eur J Biochem 1990, V193, P837 HCAPLUS (31) Scanlin, T; Biochim Biophys Acta 1999, V1455, P241 HCAPLUS (32) Spiro, R; J Biol Chem 1974, V249, P5704 HCAPLUS (33) Takasaki, S; Methods Enzymol 1978, V50, P50 HCAPLUS (34) Tsuboi, S; Bioessays 2001, V23, P46 HCAPLUS (35) Tsuji, T; Carbohydr Res 1986, V151, P391 HCAPLUS (36) Whistler, R; Adv Carbohydr Chem 1958, V13, P289 HCAPLUS (37) White, S; J Am Chem Soc 1970, V92, P4203 HCAPLUS ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN L79 2002:276758 HCAPLUS AN DN 137:311089 ED Entered STN: 14 Apr 2002 Chemical release of O-linked oligosaccharide chains TI Hounsell, Elizabeth F.; Davies, Michael J.; Smith, Kevin D. AU School of Biological and Chemical Sciences, Birkbeck University of London, CS Protein Protocols Handbook (2nd Edition) (2002), 817-818. Editor(s): SO Walker, John M. Publisher: Humana Press Inc., Totowa, N. J. CODEN: 69CLRT; ISBN: 0-89603-940-4 DT Conference; General Review English LΑ CC 33-0 (Carbohydrates) Section cross-reference(s): 6
- AB A review describes a method for the chemical release of O-linked oligosaccharides. O-linked oligosaccharides having core sequences can be released specifically from protein via a .beta .-elimination reaction catalyzed by alkali. The reaction is usually carried out with concomitant reduction to prevent peeling, a reaction

caused by further β -elimination around the ring of 3-substituted monosaccharides. The reduced oligosaccharides can be specifically bound by solid sorbent extraction on phenylboronic acid columns. review oligosaccharide chem release elimination catalyst alkali; stoligosaccharide release protein alkali review ITOligosaccharides, reactions RL: ANT (Analyte); BSU (Biological study, unclassified); RCT (Reactant); ANST (Analytical study); BIOL (Biological study); RACT (Reactant or reagent) (O-linked; chemical release of O-linked oligosaccharide chains from proteins) IT Glycoproteins RL: ANT (Analyte); BSU (Biological study, unclassified); RCT (Reactant); ANST (Analytical study); BIOL (Biological study); RACT (Reactant or reagent) (chemical release of O-linked oligosaccharide chains from proteins) IT Elimination reaction Elimination reaction catalysts (β -; chemical release of O-linked oligosaccharide chains from proteins) THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT RE (1) Hounsell, E; Adv Carbohyd Chem Biochem 1994, V30, P311 (2) Stoll, M; Biomed Chromatogr 1988, V2, P249 HCAPLUS ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN 2001:831474 HCAPLUS AN 136:151374 DN Entered STN: 16 Nov 2001 ED Microscale Non-Reductive Release of O-Linked Glycans for Subsequent Analysis through MALDI Mass Spectrometry and Capillary Electrophoresis Huang, Yunping; Mechref, Yehia; Novotny, Milos ΑU Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA CS Analytical Chemistry (2001), 73(24), 6063-6069 SO CODEN: ANCHAM; ISSN: 0003-2700 American Chemical Society PΒ DTJournal LA English CC 33-8 (Carbohydrates) Section cross-reference(s): 6, 7, 9, 22 A new β -elimination-based procedure has been AB devised for a microscale release of O-linked oligosaccharides from glycoproteins. Unlike the conventional Carlson degradation, which leads to formation of alditols, the procedure reported here renders the reducing end intact. Conversion of the liberated oligosaccharides to glycosylamines in ammonia medium is followed by the production of the reducing oligosaccharides through the addition of boric acid. The quant. generated oligosaccharides with the reducing end can subsequently be derivatized with a fluorophoric reagent for capillary electrophoresis or, alternatively, analyzed through MALDI mass spectrometry. The microscale version of these chemical steps permits us to investigate structurally O-linked oligosaccharides at very low levels. fetuin bovine asialofetuin mucin enzymic degrdn glycoprotein MALDI; neuraminic acid oligosaccharide prepn elimination enzymic glycoprotein; oligosaccharide prepn ammonia elimination enzymic glycoprotein mol structure MALDI; microscale enzymic degrdn glycan MALDI capillary electrophoresis glycoprotein IT RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)

(asialofetuins; microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Fetuins

RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent) (bovine; microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Capillary electrophoresis

Molecular structure, natural product

(microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Oligosaccharides, preparation

RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL

(Biological study); PREP (Preparation)

(microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Glycoproteins

Polysaccharides, reactions

RL: NPO (Natural product occurrence); PRP (Properties); RCT (Reactant); BIOL (Biological study); OCCU (Occurrence); RACT (Reactant or reagent)

(microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Mucins

RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent) (microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Laser ionization mass spectrometry

(photodesorption, matrix-assisted; microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Laser desorption mass spectrometry

(photoionization, matrix-assisted; microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT Elimination reaction

 $(\beta$ -; microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT 9001-62-1, Lipase

RL: CAT (Catalyst use); USES (Uses)

(human milk bile salt-stimulated; microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT 71023-10-4P 71764-07-3P 90393-57-0P 93395-38-1P 144370-37-6P 144370-40-1P 395070-69-6P 395070-70-9P 395070-71-0P 395070-72-1P 395682-10-7P 395682-11-8P 395682-13-0P 395682-14-1P

RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)

(microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT 34620-78-5, Maltoheptaose

RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent) (microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

IT **88-68-6**, 2-Aminobenzamide 51987-58-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD

(1) Baba, T; Biochemistry 1991, V30, P500 HCAPLUS

(2) Bardelmeijer, H; Electrophoresis 1997, V18, P2214 HCAPLUS (3) Bendiak, B; Carbohydr Res 1985, V144, P1 HCAPLUS (4) Bigge, J; Anal Biochem 1995, V230, P229 HCAPLUS (5) Blackberg, L; Eur J Biochem 1995, V228, P817 HCAPLUS (6) Blixt, O; Carbohydr Res 1999, V319, P80 HCAPLUS (7) Carlson, D; J Biol Chem 1968, V243, P616 HCAPLUS (8) Chai, W; Glycobiology 1997, V7, P861 HCAPLUS (9) Clark, P; Carbohydr Res 1983, V118, P147 HCAPLUS (10) Dennis, J; Bioessays 1999, V21, P412 MEDLINE (11) El Rassi; Z Electrophoresis 1999, V20, P3134 HCAPLUS (12) Feizi, T; Methods Enzymol 1994, V242, P205 HCAPLUS (13) Hanisch, F; Anal Biochem 2001, V290, P47 HCAPLUS (14) Hanisch, F; Biol Chem 2001, V382, P143 HCAPLUS (15) Hong, M; J Chromatogr, B 2001, V752, P207 HCAPLUS (16) Hounsell, E; Glycoconjugate J 1996, V13, P19 HCAPLUS (17) Huang, Y; Rapid Commun Mass Spectrom 2000, V14, P1233 HCAPLUS (18) Kallin, E; J Carbohydr Chem 1989, V8, P597 HCAPLUS (19) Kearse, K; Proc Natl Acad Sci U S A 1991, V88, P1701 HCAPLUS (20) Klockow, A; J Chromatogr, A 1995, V716, P241 HCAPLUS (21) Landberg, E; Arch Biochem Biophys 2000, V377, P246 HCAPLUS (22) Likhosherstov, L; Carbohydr Res 1986, V146, PC1 HCAPLUS (23) Liu, J; Anal Chem 1991, V63, P408 HCAPLUS (24) Lubineau, A; Carbohydr Res 1995, V266, P211 HCAPLUS (25) Mechref, Y; Anal Chem 1998, V70, P455 HCAPLUS (26) Mechref, Y; Glycobiology 1999, V9, P227 HCAPLUS (27) Mechref, Y; J Am Soc Mass Spectrom 1998, V9, P1293 HCAPLUS (28) Mechref, Y; in preparation (29) Nilsson, J; Eur J Biochem 1990, V192, P543 HCAPLUS (30) O'Neil, R; J Chromatogr, A 1996, V720, P201 (31) Patel, T; Biochemistry 1993, V32, P679 HCAPLUS(32) Patel, T; Methods Enzymol 1994, V230, P57 HCAPLUS (33) Paulus, A; J Chromatogr, A 1996, V720, P353 HCAPLUS (34) Rademaker, G; Anal Biochem 1998, V257, P149 HCAPLUS (35) Savitzky, A; Anal Chem 1964, V36, P1627 HCAPLUS (36) Spiro, R; J Biol Chem 1974, V249, P5704 HCAPLUS (37) Stefansson, M; Carbohydr Res 1994, V258, P1 HCAPLUS (38) Stubbs, H; Anal Biochem 1997, V247, P357 HCAPLUS (39) Takahashi, N; Handbook of Endoqlycosidases and Glycoamidases 1992, P183 (40) Takasaki, S; Biochemistry 1986, V25, P5709 HCAPLUS (41) Takasaki, S; Methods Enzymol 1978, V50, P50 HCAPLUS (42) Torres, C; J Biol Chem 1984, V259, P3308 HCAPLUS (43) Tsuji, T; Carbohydr Res 1986, V151, P391 HCAPLUS (44) Umemoto, J; J Biol Chem 1977, V252, P8609 HCAPLUS (45) Varki, A; Glycobiology 1993, V3, P97 HCAPLUS (46) White, C; An Introduction to the Chemistry of Carbohydrates, 3rd ed 1988, (47) Whittal, R; Anal Chem 1995, V67, P3509 HCAPLUS (48) Yoshino, K; Anal Chem 1995, V67, P4028 HCAPLUS **34620-78-5**, Maltoheptaose RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent) (microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis) RN34620-78-5 HCAPLUS CN D-Glucose, $O-\alpha$ -D-glucopyranosyl- $(1\rightarrow 4)$ - $O-\alpha$ -Dglucopyranosyl - $(1\rightarrow 4)$ -0- α -D-glucopyranosyl - $(1\rightarrow 4)$ -0-

NAME)

 α -D-glucopyranosyl-(1 \rightarrow 4)-O- α -D-glucopyranosyl-(1 \rightarrow 4)-O- α -D-glucopyranosyl-(1 \rightarrow 4)- (9CI) (CA INDEX

PAGE 1-B

ΙT 88-68-6, 2-Aminobenzamide

RL: RCT (Reactant); RACT (Reactant or reagent) (microscale non-reductive release of O-linked glycans for subsequent anal. through MALDI mass spectrometry and capillary electrophoresis) 88-68-6 HCAPLUS

RN

(CA INDEX NAME) CN Benzamide, 2-amino- (9CI)

L79 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

1999:726017 HCAPLUS AN

DN 132:75619

Entered STN: 15 Nov 1999 ED

Preparation and isolation of neoglycoconjugates using biotin-streptavidin ΤI

Kuberan, B.; Gunay, N. S.; Dordick, J. S.; Linhardt, R. J. ΑU

Division of Medicinal and Natural Products Chemistry and Department of CS Chemical and Biochemical Engineering, University of Iowa, Iowa City, IA, 52242, USA

SO Glycoconjugate Journal (1999), 16(6), 271-281 CODEN: GLJOEW; ISSN: 0282-0080

Kluwer Academic Publishers PB

Journal DT

English LA

```
9-14 (Biochemical Methods)
     Section cross-reference(s): 6, 33, 34
     Glycoproteins com. available in multi-gram quantities, were used
AB
     to prepare milligram amts. of neoglycoproteins. The glycoproteins
     bromelain and bovine \gamma-globulin were proteolyzed to obtain
     glycopeptides or converted to a mixture of glycans through hydrazinolysis.
     The glycan mixture was structurally simplified by carbohydrate
     remodeling using exoglycosidases. Glycopeptides were biotinylated using
     N-hydroxysuccinimide activated-long chain biotin while
     glycoprotein-derived glycans were first reductively aminated with
     ammonium bicarbonate and then biotinylated. The
     resulting biotinylated carbohydrates were structurally
     characterized and then bound to streptavidin to afford neoglycoproteins.
     The peptidoglycan component of raw, unbleached heparin (an intermediate in
     the manufacture of heparin) was similarly biotinylated and bound to
     streptavidin to obtain milligram amts. of a heparin neoproteoglycan.
     neoglycoconjugates prepared contain well defined glycan chains at specific
     locations on the streptavidin core and should be useful for the study of
     protein-carbohydrate interactions and affinity sepns.
ST
     neoglycoconjugate prepn glycoprotein carbohydrate
     biotin streptavidin
     Immunoglobulins
IT
     RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU
     (Biological study, unclassified); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
        (G; preparation and isolation of neoglycoconjugates using
       biotin-streptavidin complexes)
TT
     Glycoproteins, specific or class
     RL: BPN (Biosynthetic preparation); BPR (Biological process);
     BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL
     (Biological study); PREP (Preparation); PROC (Process)
        (neoglycoproteins; preparation and isolation of neoglycoconjugates using
        biotin-streptavidin complexes)
IT
     Carbohydrates, analysis
       Oligosaccharides, analysis
     RL: ARU (Analytical role, unclassified); BPN (Biosynthetic
     preparation); BPR (Biological process); BSU (Biological study,
     unclassified); BUU (Biological use, unclassified); SPN (Synthetic
     preparation); ANST (Analytical study); BIOL (Biological study);
     PREP (Preparation); PROC (Process); USES (Uses)
        (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
IT
    Glycopeptides
       Glycoproteins, general, biological studies
     Peptidoglycans
     RL: BPN (Biosynthetic preparation); BPR (Biological process);
     BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL
     (Biological study); PREP (Preparation); PROC (Process)
        (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
IT
     Globulins, biological studies
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (\gamma-; preparation and isolation of neoglycoconjugates using
        biotin-streptavidin complexes)
                      9013-20-1, Streptavidin
IT
     58-85-5, Biotin
     RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU
     (Biological study, unclassified); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
        (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
     52769-52-5, Exoglycosidase
IT
```

RL: BAC (Biological activity or effector, except adverse); BPR (Biological

```
process); BSU (Biological study, unclassified); BIOL (Biological study);
     PROC (Process)
         (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
                                   84825-26-3P
                                                   254116-49-9P
TΤ
     70858-45-6P
                    79295-70-8P
                                                                   254116-51-3P
     254116-52-4P
     RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU
     (Biological study, unclassified); RCT (Reactant); SPN (Synthetic
     preparation); BIOL (Biological study); PREP (Preparation); PROC (Process);
     RACT (Reactant or reagent)
         (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
     9005-49-6P, Heparin, biological studies
IT
                                                  254116-50-2P
                                                                   254116-53-5P
     254116-54-6P
     RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU
     (Biological study, unclassified); SPN (Synthetic preparation); BIOL
     (Biological study); PREP (Preparation); PROC (Process)
         (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
     150977-36-9, Bromelain
IT
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
         (preparation and isolation of neoglycoconjugates using biotin-streptavidin
        complexes)
               THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
RE
(1) Al-Hakim, A; Appl Theoret Electrophor 1991, V1, P305 HCAPLUS
(2) Bay, S; Carbohydr Res 1997, V298, P153 HCAPLUS
(3) Caldwell, E; Arch Biochem Biophys 1999, V361, P215 MEDLINE
(4) Chandrasekhar, S; Anal Biochem 1987, V161, P103 HCAPLUS
(5) Chen, V; Biochemistry 1986, V25, P939 HCAPLUS(6) Choe, J; AlChE J 1998, V44, P2542 HCAPLUS
(7) Cummings, R; Methods in Enzymology 1994, V230, P66 HCAPLUS
(8) Fedarko, N; Experientia 1993, V49, P369 HCAPLUS
(9) Fujii, S; J Biol Chem 1990, V265, P6009 HCAPLUS
(10) Garcia-Cascado, G; Glycobiology 1996, V6, P471
(11) Gerber, S; J Am Chem Soc 1999, V121, P1102 HCAPLUS
(12) Hasegawa, Y; Chemistry Lett 1996, P40
(13) Hounsell, D; Adv Exper Med & Biol 1998, V435, P251
(14) Iozzo, R; Ann Rev Biochem 1998, V67, P609 HCAPLUS
(15) Jenkins, N; Nature Biotechnol 1996, V14, P975 HCAPLUS
(16) Kawaguchi, K; J Biol Chem 1981, V265, P2230
(17) Kobata, A; Glycoconjugate J 1998, V15, P323 HCAPLUS
(18) Lee, K; Appl Biochem Biotechnol 1990, V23, P53 HCAPLUS
(19) Lee, Y; Neoglycoconjugates: Preparation and Application 1994
(20) Leteux, C; Glycobiology 1998, V8, P227 HCAPLUS
(21) Linhardt, R; Carbohydrates as Drugs 1997, P277 HCAPLUS
(22) Linhardt, R; Chem & Indust 1991, V2, P45
(23) Liu, J; Glycobiology 1995, P765 HCAPLUS
(24) Lommerse, J; Biochemistry 1995, V34, P8196 HCAPLUS
(25) Masson, L; Anal Biochem 1994, V218, P405 HCAPLUS
(26) Moens, S; Arch Microbiol 1997, V168, P169 HCAPLUS
(27) Nadkarni, V; Biotechniques 1996, V23, P382
(28) Nelson, R; Annu Rev Cell Dev Biol 1995, V11, P601 HCAPLUS
(29) Quesenberry, M; Biochemistry 1997, V36, P2724 HCAPLUS (30) Ripellino, J; Neurochem 1989, V52, P807 HCAPLUS
(31) Schneller, M; Biol Chem Hoppe-Seyler 1992, V373, P1095 HCAPLUS
(32) Sears, P; Cellular & Molec Life Sci 1998, V54, P223 HCAPLUS
(33) Shinohara, T; J Biochem 1995, V117, P1076
(34) Shinohara, Y; Anal Chem 1996, V68, P2573 HCAPLUS
(35) Toomre, D; Glycobiology 1994, V4, P653 HCAPLUS
(36) Wadhwa, M; J Drug Targeting 1995, V3, P111 HCAPLUS
```

(37) Wolff, M; Prep Biochem 1999, V29, P1 HCAPLUS

```
(38) Wong, S; Biochem J 1993, V296, P817 HCAPLUS
(39) Wong, S; Curr Opin Struct Biol 1995, V5, P599 HCAPLUS
L79 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:2141 HCAPLUS
DN 130:165080
ED Entered STN: 04 Jan 1999
```

TI A general approach to desalting **oligosaccharides** released from **glycoproteins**

AU Packer, Nicolle H.; Lawson, Margaret A.; Jardine, Daniel R.; Redmond, John W.

CS Macquarie University Centre for Analytical Biotechnology, School of Biological Sciences, Macquarie University, Sydney, NSW 2109, Australia

SO Glycoconjugate Journal (1998), 15(8), 737-747 CODEN: GLJOEW; ISSN: 0282-0080

PB Kluwer Academic Publishers

DT Journal

LA English

CC 9-9 (Biochemical Methods)
Section cross-reference(s): 6, 7, 33

- Desalting of sugar samples is essential for the success of many AB techniques of carbohydrate anal. such as mass spectrometry, capillary electrophoresis, anion exchange chromatog., enzyme degradation and chemical derivatization. All desalting methods which are currently used have limitations for example, mixed-bed ion-exchange columns risk the loss of charged sugars, precipitation of salt by a non-aqueous solvent can result in co-precipitation of oligosaccharides, and gel chromatog. uses highly crosslinked packings in which separation of small oligosaccharides is difficult to achieve. We demonstrate that graphitized carbon as a solid phase extraction cartridge can be used for the purification of oligosaccharides (or their derivs.) from solns. containing one or more of the following contaminants: salts (including salts of hydroxide, acetate, phosphate), monosaccharides, detergents (SDS and Triton X-100), protein (including enzymes) and reagents for the release of oligosaccharides from glycoconjugates (such as hydrazine and sodium borohydride). There is complete recovery of the oligosaccharides from the adsorbent which can also be used to fractionate acidic and neutral glycans. Specific applications such as clean-up of N-linked oligosaccharides after removal by PNGase F and hydrazine, desalting of O-linked glycans after removal by alkali, online desalting of HPAEC-separated oligosaccharides and . beta.-eliminated alditols prior to electrospray mass spectrometry, and purification of oligosaccharides from urine are described.
- ST oligosaccharide desalting glycoprotein anion exchange chromatograph mass spectrometry
- IT Glycophorins
 RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)
 - (A; general approach to desalting **oligosaccharides** released from **glycoproteins**)

IT Graphitized carbon black
 RL: ARU (Analytical role, unclassified); BUU (Biological use,
 unclassified); NUU (Other use, unclassified); ANST (Analytical study);
 BIOL (Biological study); USES (Uses)

(Carbograph, non-porous; general approach to desalting oligosaccharides released from glycoproteins)

IT Salts, analysis
RL: ARU (Analytical role, unclassified); REM (Removal or disposal); ANST
(Analytical study); PROC (Process)

(desalting; general approach to desalting oligosaccharides released from glycoproteins)

```
IT
    Anion exchange HPLC
    Electrospray ionization mass spectrometry
        (general approach to desalting oligosaccharides released from
        glycoproteins)
TT
    Fetuins
       Glycoproteins, general, analysis
     Ovalbumin
    RL: ANT (Analyte); BPR (Biological process); BSU (Biological
     study, unclassified); ANST (Analytical study); BIOL (Biological study);
    PROC (Process)
        (general approach to desalting oligosaccharides released from
        glycoproteins)
ΙT
    Oligosaccharides, analysis
    RL: ANT (Analyte); BPR (Biological process); BSU (Biological study,
    unclassified); PUR (Purification or recovery); ANST (Analytical
     study); BIOL (Biological study); PREP (Preparation); PROC
     (Process)
        (general approach to desalting oligosaccharides released from
        glycoproteins)
IT
    Amino acids, analysis
    RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU
     (Biological study, unclassified); ANST (Analytical study); BIOL
     (Biological study); PROC (Process)
        (general approach to desalting oligosaccharides released from
        glycoproteins)
     Proteins, general, analysis
TΤ
    RL: ARU (Analytical role, unclassified); BSU (Biological study,
     unclassified); REM (Removal or disposal); ANST (Analytical study); BIOL
     (Biological study); PROC (Process)
        (general approach to desalting oligosaccharides released from
        glycoproteins)
TΨ
    Graphitized carbon black
    RL: ARU (Analytical role, unclassified); BUU (Biological use,
     unclassified); NUU (Other use, unclassified); ANST (Analytical study);
    BIOL (Biological study); USES (Uses)
        (porous; general approach to desalting oligosaccharides
        released from glycoproteins)
IT
    Albumins, analysis
    RL: ANT (Analyte); BPR (Biological process); BSU (Biological study,
     unclassified); ANST (Analytical study); BIOL (Biological study); PROC
     (Process)
        (serum; general approach to desalting oligosaccharides
        released from glycoproteins)
IT
    Extraction
        (solid-phase; general approach to desalting oligosaccharides
        released from glycoproteins)
     83534-39-8, PNGase F
    RL: ARU (Analytical role, unclassified); BAC (Biological activity or
     effector, except adverse); BPR (Biological process); BSU (Biological
     study, unclassified); REM (Removal or disposal); ANST (Analytical study);
     BIOL (Biological study); PROC (Process)
        (general approach to desalting oligosaccharides released from
        glycoproteins)
ΙT
    119683-99-7, Hypercarb
    RL: ARU (Analytical role, unclassified); BUU (Biological use,
    unclassified); NUU (Other use, unclassified); ANST (Analytical study);
    BIOL (Biological study); USES (Uses)
        (general approach to desalting oligosaccharides released from
        glycoproteins)
    302-01-2, Hydrazine, analysis
    RL: ARU (Analytical role, unclassified); RCT (Reactant); REM (Removal or
    disposal); ANST (Analytical study); PROC (Process); RACT (Reactant or
```

reagent)

(general approach to desalting oligosaccharides released from glycoproteins)

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 29 RE

- (1) Anson, D; Biochem J 1992, V284, P789 HCAPLUS
- (2) Bertolini, M; J Biol Chem 1967, V242, P3776 MEDLINE
- (3) Bornsen, K; Rapid Comm Mass Spectrom 1995, V9, P1031
- (4) Chen, L; FASEB J 1988, V2, P2819 HCAPLUS
- (5) Crescenzi, C; J Chromatog A 1996, V733, P41 HCAPLUS
- (6) Da Silva, M; Arch Biochem Biophys 1995, V318, P465 HCAPLUS
- (7) Davies, M; J Chromatog 1992, V609, P125 HCAPLUS
- (8) Davies, M; J Chromatog 1993, V646, P317 HCAPLUS
- (9) Fan, J; Anal Biochem 1994, V219, P224 HCAPLUS
- (10) Feigl, F; Spot Tests in Organic Analysis 7th Edition 1966, P274
- (11) Grewal, T; Atherosclerosis 1995, V121, P151
- (12) Knox, J; J Chromatog 1986, V352, P3 HCAPLUS (13) Knox, J; J Chromatog 1986, V352, P3 HCAPLUS
- (14) Koizumi, K; Carbohydr Res 1991, V215, P67 HCAPLUS
- (15) Koizumi, K; J Chromatog A 1996, V720, P119 HCAPLUS
- (16) Kuster, B; J Mass Spectrom 1996, V31, P1131 MEDLINE
- (17) Lee, Y; J Chromatog A 1996, V720, P137 HCAPLUS
- (18) Ou, K; J Chromatog A 1996, V723, P219 HCAPLUS
- (19) Packer, N; Electrophoresis 1998, V19, P981 HCAPLUS
- (20) Papac, D; Techniques in Glycobiology 1997, P33 HCAPLUS
- (21) Patel, T; Biochemistry 1993, V32, P679 HCAPLUS
- (22) Peelen, G; Clin Chem 1994, V40, P914 HCAPLUS
- (23) Pisano, A; Glycobiology 1993, V3, P429 HCAPLUS
- (24) Rouse, J; Anal Biochem 1996, V238, P82 HCAPLUS
- (25) Shahqholi, M; Anal Chem 1996, V68, P1335 HCAPLUS
- (26) Shively, J; Methods of Protein Characterization 1986
- (27) Spiro, R; J Biol Chem 1966, V239, P567
- (28) Townsend, R; Anal Biochem 1989, V182, P1 HCAPLUS
- (29) Whistler, R; Methods in Carbohydrate Chemistry 1962, V1, P42 HCAPLUS
- L79 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
- 1998:617882 HCAPLUS AN
- DN 129:302788
- Entered STN: 30 Sep 1998 ED
- The synthesis and enzymic incorporation of sialic acid derivatives for use TI as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates
- ΑU Martin, Richard; Witte, Krista L.; Wong, Chi-Huey
- Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
- Bioorganic & Medicinal Chemistry (1998), 6(8), 1283-1292 SO CODEN: BMECEP; ISSN: 0968-0896
- Elsevier Science Ltd. PΒ
- DT Journal
- LA English
- CC 33-8 (Carbohydrates) Section cross-reference(s): 7, 9
- Methods have been developed for the enzymic synthesis of complex AB carbohydrates and glycoproteins containing in the sialic acid moiety the heavy metal mercury or the transition-state analog phosphonate of the influenza C 9-O-acetyl-neuraminic acid esterase-catalyzed reaction. 5-Acetamido-3,5-dideoxy-9-methylphosphonoβ-D-glycero-D-galacto-nonulopyranosidonic acid (1), 5-acetamido-3,5-dideoxy-9-methylphosphono-2-propyl-α-D-glycero-Dgalacto-nonulopyranosidonic acid triethylammonium salt (2), and 5-acetamido-9-thiomethylmercuric-3,5,9-trideoxy-β-D-glycero-D-galactononulopyranosidonic acid (3) were synthesized. Compds. 1 and 2 are proposed transition state inhibitors of an esterase vital for the binding

and infection of influenza C. Compound 3 was enzymically incorporated into an oligosaccharide and a non-natural glycoprotein for use as an aid in the structure determination of these compds. by X-ray crystallog. mol structure glycoprotein oligosaccharide sialic acid; esterase inhibitor sialic acid glycoprotein synthesis; sialic acid glycoprotein enzymic synthesis IT Molecular structure (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) IT Glycoconjugates Sialooligosaccharides RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) Glycoproteins, general, biological studies RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) IT 214542-04-8P RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) 214542-05-9P 214542-06-0DP, RNase-bound 214542-07-1P IT 214542-03-7P RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) 89400-31-7, 9-O-Acetylsialic acid esterase IT RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) IT 9001-78-9 9067-82-7 68247-53-0 71124-51-1 163559-38-4D, RNase-bound RL: CAT (Catalyst use); USES (Uses) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) TT 65-47-4, Ctp 15839-70-0, Gdp-fucose 19342-33-7 71496-53-2 156521-67-4 RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) IT22900-11-4P 131087-75-7P 183001-30-1P 214541-95-4P 214541-98-7P 214541-99-8P 214542-01-5P 214542-02-6P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates) 214541-92-1P 214541-94-3P TT

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis and enzymic incorporation of sialic acids for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates)

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Ashwell, G; Ann Rev Biochem 1982, V51, P531 HCAPLUS
- (2) Auge, C; Carbo Res 1989, V193, P288 HCAPLUS
- (3) Breg, J; J Biochem 1989, V178, P727 HCAPLUS
- (4) Deisenhofer, J; Hoppe-Seyler's Z Physiol 1976, P357
- (5) Deslongchamps, P; Pure Appl Chem 1993, V65, P1161 HCAPLUS
- (6) Fitz, W; Bioorg Med Chem 1996, V4, P1349 HCAPLUS
- (7) Gottschalk, A; Biochim Biophys Acta 1957, V23, P645 HCAPLUS
- (8) Gross, H; Eur J Biochem 1987, V168, P595 HCAPLUS
- (9) Gross, H; Eur J Biochem 1988, V177, P583 HCAPLUS
- (10) Hayes, B; J Biol Chem 1989, V264, P19443 HCAPLUS
- (11) Herrler, G; EMBO 1985, V4, P1503 HCAPLUS
- (12) Hirst, G; J Exp Med 1950, V91, P177
- (13) Ichikawa, Y; J Am Chem Soc 1992, V114, P9283 HCAPLUS
- (14) Imhof, A; Biol Chem Hoppe-Seyler Supplement 1988, V369, P841
- (15) Kamerling, J; Pure Appl Chem 1994, V55, P2235
- (16) Klenk, E; Physiol Chem 1955, V301, P235 HCAPLUS
- (17) Kuhn, R; Chem Ber 1966, V99, P611 HCAPLUS
- (18) Lin, C; Bioorg Med Chem 1995, V3, P1625 HCAPLUS
- (19) Liu, J; J Am Chem Soc 1992, V114, P3901 HCAPLUS
- (20) Lowe, J; Carbohydrate Recognition in Cell-Cell Interaction 1994, P163 HCAPLUS
- (21) Muchmore, E; Science 1987, V236, P1293 HCAPLUS
- (22) Murray, B; Biochemistry 1996, V35, P11183 HCAPLUS
- (23) Murray, B; Biochemistry 1997, P36
- (24) Okamoto, K; Tetrahedron 1990, V46, P5835 HCAPLUS
- (25) Palcic, M; J Biol Chem 1989, V264, P17174 HCAPLUS
- (26) Pardoe, G; J Med Lab Technol 1970, V27, P249 HCAPLUS
- (27) Paulson, J; The Receptors 1985, V2, P131 HCAPLUS
- (28) Poppe, L; Eur J Biochem 1989, V180, P337 HCAPLUS
- (29) Qiao, L; J Am Chem Soc 1996, V118, P7653 HCAPLUS
- (30) Ravindranath, M; J Biol Chem 1985, V260, P8850 HCAPLUS
- (31) Rogers, G; J Biol Chem 1986, V261, P5947 HCAPLUS
- (32) Roseman, S; Proc Natl Acad Sci U S A 1962, V48, P437 HCAPLUS
- (33) Rosenburg, A; Biology of the Sialic Acids 1995
- (34) Rosenthal, P; Acta Cryst 1996, V52, P1041 MEDLINE
- (35) Rosenthal, P; Nature, submitted 1996
- (36) Roy, R; Carbo Chem 1987, V6, P161 HCAPLUS
- (37) Shigeta, R; Acta Cryst 1994, V50, P71
- (38) Sinnott, M; Chem Rev 1990, V90, P1171 HCAPLUS
- (39) Takayama, S; Bioorg Med Chem Lett 1996, V6, P1123 HCAPLUS
- (40) van der Vleugel, D; Carbo Res 1982, V102, P121 HCAPLUS
- (41) Varki, A; Glycobiology 1993, V3, P97 HCAPLUS
- (42) Vlasak, R; J Virol 1989, V63, P2056 HCAPLUS
- (43) Vlasak, R; Virology 1987, V160, P419 HCAPLUS
- (44) Wilson, I; Nature 1981, V289, P366 HCAPLUS
- (45) Witte, K; J Am Chem Soc 1997, V119, P3842
- L79 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
- AN 1998:589889 HCAPLUS
- DN 129:290322
- ED Entered STN: 17 Sep 1998
- TI Structural Analysis of **Oligosaccharides** Derivatized with 4-Aminobenzoic Acid 2-(Diethylamino)ethyl Ester by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry
- AU Mo, Wenjun; Takao, Toshifumi; Sakamoto, Hiroko; Shimonishi, Yasutsugu
- CS Institute for Protein Research, Osaka University, Osaka, 565-0871, Japan
- SO Analytical Chemistry (1998), 70(21), 4520-4526
 - CODEN: ANCHAM; ISSN: 0003-2700

```
American Chemical Society
PB
DT
     Journal
     English
LA
     33-4 (Carbohydrates)
CC
     Section cross-reference(s): 22
     Oligosaccharides derivatized with 4-aminobenzoic acid
AB
     2-(diethylamino) Et ester (ABDEAE) can be analyzed by ESI and MALDI mass
     spectrometry. In this study, oligosaccharides derived from the
     enzymic cleavage of the sugar chains of
     qlycoproteins RNase B, erythropoietin, and transferrin were
     subjected to ABDEAE derivatization, prior to anal. on a matrix-assisted
     laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF
     MS) for high-resolution mass measurement and a post-source decay (PSD)
experiment
     In the mass measurement of ABDEAE derivs., quasi-mol. ion species have
     been observed in mono-isotopic resolution using 2,5-dihydroxybenzoic acid as
the
     matrix from spots that contain 50-200 fmol of sample; in the PSD analyses
     from the spots contained 500 fmol-1 pmol of sample, the predominant
     backbone ion series which covers the entire mass range for all the
     derivs., the internal ion series which reflect the branched tri-mannosyl
     core structure of N-glycans, and the low m/z fingerprint ion of ABDEAE
     were consecutively observed, permitting structure elucidation of the
     oligosaccharides. Given the effectiveness of this derivatization
     in terms of its high sensitivity and resolution with respect to MALDI-TOF MS,
     current methodol. is clearly applicable to the sensitive detection and accurate structural anal. of N-glycans.
     MALDI glycoprotein oligosaccharide structural analysis
ST
     ABDEAE
     Laser ionization mass spectrometry
ΙT
        (photodesorption, matrix-assisted; structural anal. of
        oligosaccharides derivatized with 4-aminobenzoic acid
        2-(diethylamino)ethyl ester by matrix-assisted laser
        desorption/ionization mass spectrometry)
IT
     Laser desorption mass spectrometry
        (photoionization, matrix-assisted; structural anal. of
        oligosaccharides derivatized with 4-aminobenzoic acid
        2-(diethylamino)ethyl ester by matrix-assisted laser
        desorption/ionization mass spectrometry)
     Molecular structure
IT
        (structural anal. of oligosaccharides derivatized with
        4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
        laser desorption/ionization mass spectrometry)
IT
     Oligosaccharides, preparation
     RL: ANT (Analyte); BPN (Biosynthetic preparation); ANST
     (Analytical study); BIOL (Biological study); PREP (Preparation)
        (structural anal. of oligosaccharides derivatized with
        4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
        laser desorption/ionization mass spectrometry)
IT
     Glycoproteins, general, reactions
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (structural anal. of oligosaccharides derivatized with
        4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
        laser desorption/ionization mass spectrometry)
IT
     Transferrins
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (structural anal. of oligosaccharides from by matrix-assisted
        laser desorption/ionization mass spectrometry)
IT
     9001-99-4
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (B; structural anal. of oligosaccharides from by
       matrix-assisted laser desorption/ionization mass spectrometry)
     83534-39-8, Pngase f
IT
```

```
RL: CAT (Catalyst use); USES (Uses)
        (preparation of oligosaccharides for derivatization for
       matrix-assisted laser desorption/ionization mass spectrometry)
                                                            84182-22-9DP,
                  78392-81-1DP, galacto-aminoglucosylated
IT
    mannosylated
    RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological
     study); PREP (Preparation); RACT (Reactant or reagent)
        (structural anal. of oligosaccharides derivatized with
       4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
       laser desorption/ionization mass spectrometry)
IT
    214264-99-0
    RL: PRP (Properties)
        (structural anal. of oligosaccharides derivatized with
       4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
       laser desorption/ionization mass spectrometry)
     214264-90-1DP, mannosylated 214264-92-3DP, galacto-aminoglucosylated
     214264-94-5P
    RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic
    preparation); PREP (Preparation)
        (structural anal. of oligosaccharides derivatized with
        4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
       laser desorption/ionization mass spectrometry)
    51-05-8
TT
    RL: RCT (Reactant); RACT (Reactant or reagent)
        (structural anal. of oligosaccharides derivatized with
       4-aminobenzoic acid 2-(diethylamino)ethyl ester by matrix-assisted
       laser desorption/ionization mass spectrometry)
     11096-26-7, Erythropoietin
IT
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (structural anal. of oligosaccharides from by matrix-assisted
        laser desorption/ionization mass spectrometry)
             THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
RE
(1) Cumming, D; Glycobiology 1991, V1, P115 HCAPLUS
(2) Dell, A; Biomed Environ Mass Spectrom 1988, V16, P19 MEDLINE
(3) Domon, B; Glycoconjugate J 1988, V5, P397 HCAPLUS
(4) Fenn, J; J Am Soc Mass Spectrom 1993, V4, P524 HCAPLUS
(5) Harvey, D; J Mass Spectrom 1995, V30, P1311 HCAPLUS
(6) Hillenkamp, F; Methods Enzymol 1990, V193, P280 HCAPLUS
(7) Karas, M; Int J Mass Spectrom Ion Processes 1987, V78, P53 HCAPLUS
(8) Kussmann, M; J Mass Spectrom 1997, V32, P593 HCAPLUS
(9) Lemonie, J; J Mass Spectrom 1996, V31, P908
(10) Mo, W; Rapid Commun Mass Spectrom 1997, V11, P1829 HCAPLUS
(11) Okafo, G; Anal Chem 1996, V68, P4424 HCAPLUS
(12) Okamoto, M; Anal Chem 1997, V69, P2919 HCAPLUS
(13) Powell, A; Rapid Commun Mass Spectrom 1996, V10, P1027 HCAPLUS
(14) Rouse, J; Anal Biochem 1998, V256, P33 HCAPLUS
(15) Sakamoto, H; Proc 46th ASMS Conf Mass Spectrom Allied Topics 1998
(16) Sasaki, H; J Biol Chem 1987, V262, P12059 HCAPLUS
(17) Takao, T; Rapid Commun Mass Spectrom 1996, V10, P637 HCAPLUS
(18) Whitehouse, C; Anal Chem 1985, V57, P675 HCAPLUS
(19) Yoshino, K; Anal Chem 1995, V67, P4028 HCAPLUS
    ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
L79
AN
     1969:78285 HCAPLUS
DN
     70:78285
     Entered STN: 12 May 1984
ED
     Two new oligosaccharides obtained from an Le(super a) -active
TI
     glycoprotein
ΑU
     Marr, Anne M. S.; Donald, Alastair S. R.; Morgan, Walter T. J.
CS
    Lister Inst. Prev. Med., London, UK
     Biochemical Journal (1968), 110(4), 789-91
SO
```

CODEN: BIJOAK; ISSN: 0264-6021

```
DT
         Journal
LA
         English
         33 (Carbohydrates)
CC
         Following serial chromatog., in order, on a Sephadex G-15 column, on
AB
         paper, and on a charcoal-Celite (c-C; 1:1) column, and further
         fractionation of the material obtained from the 1st 1. c-C eluant (EtOH
         5%) by gel filtration on columns of Sephadex G-15 and Bio-Gel P-2 and,
         finally, by repeated preparative paper chromatog. (ppc), the diffusible
         material from a continuously degraded and dialyzed solution of a Lea-active
         glycoprotein dissolved in 1100 ml. poly-(vinylbenzyl)
         triethylammonium carbonate (pH 8.6) yielded 2
         disaccharides, 0-\beta-D-galactosyl-(1 \rightarrow
         4)-2-acetamido-2-deoxy-D-glucose(N-acetyl-lactosamine) and
         O-\beta-D-galactosyl-(1 \rightarrow 3)-2-acetamido-2-deoxy-D-galactose.
         3rd component, also isolated at this time, although chromatographically
         pure and electrophoretically homogeneous, was nevertheless contaminated
         with noncarbohydrate material; the oligosaccharide component in
         the material was a tetrasaccharide lacking in Lea activity and
         identified as O-\beta-D-galactosyl-(1 \rightarrow 4)-[O-L-fucosyl-(1 \rightarrow 4)-[
         \rightarrow 3)]-O-(2-acetamido-2-deoxy-\beta-D-glucosyl)-(1 \rightarrow
         3)-D-galactose. One fraction in the material recovered from the
         subsequent fractions eluted from the c-C column with EtOH 5% and
         repeatedly chromatographed on a Bio-Gel P-2 column was further purified by
         ppc to yield a homogeneous crystalline trisaccharide with a proposed
         structure of O-\beta-D-galactosyl-(1 \rightarrow 4)-O-(N-acetyl-
         glucosaminyl) - (1 \rightarrow 6) -N-acetyl-D-galactosamine (I). A chromogenic
         material with similar properties, obtained from the 15%-EtOH eluate from
         the c-C column and further purified in the same way as I, was given the
         proposed structure of O-\beta-D-galactosyl-(1 \rightarrow
         4)-N-acetyl-D-glucosaminyl-(1 \rightarrow 6)-R (II), where R is a chromogenic
         structure. I and II, at a dilution of 1:1600, inhibited the precipitation
reaction
         between Lea blood-group substance (diluted 1:10,000) and undild. horse
         anti-(type XIV pneumococcal) serum. N-Acetyllactosamine gave comparable
          inhibition on a weight basis, whereas O-\beta-D-galactosyl-(1 
ightarrow
          3)-N-acetyl-D-qlucosamine was virtually inactive in the test system, which
          further supported the conclusion that N-acetyl-lactosamine was the
         disaccharide unit at the nonreducing end of I and of II derived
         from it.
st
         glycoprotein oligosaccharides;
         oligosaccharides glycoprotein; protein
         oligosaccharides
IT
         Oligosaccharides
         RL: RCT (Reactant); RACT (Reactant or reagent)
                (of glycoproteins, structure of)
IT
         Glycoproteins
         RL: RCT (Reactant); RACT (Reactant or reagent)
                (oligosaccharides of, structure of)
                                                             23262-91-1P 23425-36-7P
IT
         4307-58-8P
                                20972-29-6P
         RL: PREP (Preparation)
                (from glycoproteins)
IT
         4307-58-8P
         RL: PREP (Preparation)
                (from glycoproteins)
RN
         4307-58-8 HCAPLUS
         D-Glucopyranose, 2-(acetylamino)-2-deoxy-4-O-β-D-galactopyranosyl-
CN
                     (CA INDEX NAME)
```

Absolute stereochemistry.

```
=> d 180 all hitstr tot
```

```
ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
L80
ΑN
      2004:414521 HCAPLUS
DN
      140:402818
      Entered STN: 21 May 2004
ED
      High-temperature incubation apparatus for small volumes of liquids and use
ΤI
      for removal of oligosaccharides from a glycoprotein
      Huang, Yunping; Mechref, Yehia S.; Novotny, Milos
IN
PA
SO
      U.S. Pat. Appl. Publ., 9 pp.
      CODEN: USXXCO
DT
      Patent
      English
LΑ
IC
      ICM C12M001-34
NCL
      435287200
      9-1 (Biochemical Methods)
CC
FAN.CNT 1
                                                            APPLICATION NO.
      PATENT NO.
                                  KIND
                                            DATE
                                                                                            DATE
                                  ----
                                            _____
                                                             ______
                                                                                            20030819
                                                            US 2003-643501
PΙ
      US 2004096961
                                   A1
                                            20040520
                                                            WO 2003-US34087
                                                                                            20031024
      WO 2004046842
                                   A1
                                            20040603
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
            RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
                 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-426958P
                                   Ρ
                                            20021115
      US 2003-643501
                                   Α
                                            20030819
CLASS
 PATENT NO.
                       CLASS
                                 PATENT FAMILY CLASSIFICATION CODES
                                 .......
                       ----
                       ICM
                                 C12M001-34
 US 2004096961
                                 435287200
                       NCL
```

AB An apparatus and method of incubating a liquid is provided. The apparatus is well-suited for incubating small vols. (0.5-100 μ L) of liquid at high temps. The incubator and method of the invention permits chemical reactions in small vols. without substantial loss of reagents due to evaporation The liquid may be a reaction mixture comprising a glycoprotein. During the incubation process, oligosaccharides may be removed from the

```
glycoprotein.
     incubator liq small vol reaction oligosaccharide
ST
     glycoprotein
IT
     Safety devices
        (closure devices; high-temperature incubation apparatus for small vols. of
liqs.
       and use for removal of oligosaccharides from
       glycoprotein)
TT
    Gases
        (evaporation and condensation; high-temperature incubation apparatus for
small vols. of
       liqs. and use for removal of oligosaccharides from
       glycoprotein)
IT
     Condensation (physical)
     Containers
     Evaporation
    Heating
    Holders
    Liquids
    Reactors
     Seals (parts)
        (high-temperature incubation apparatus for small vols. of liqs. and use for
        removal of oligosaccharides from glycoprotein)
IT
     Glycoproteins
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (high-temperature incubation apparatus for small vols. of ligs. and use for
        removal of oligosaccharides from glycoprotein)
     Oligosaccharides, processes
IT
     RL: REM (Removal or disposal); PROC (Process)
        (high-temperature incubation apparatus for small vols. of liqs. and use for
       removal of oligosaccharides from glycoprotein)
TТ
    Heaters
        (incubators; high-temperature incubation apparatus for small vols. of liqs.
and
       use for removal of oligosaccharides from glycoprotein
IT
    Vials
        (sealable; high-temperature incubation apparatus for small vols. of liqs.
and use
        for removal of oligosaccharides from glycoprotein)
     Centrifuges
IT
        (tubes, microcentrifuge tubes; high-temperature incubation apparatus for
small
       vols. of liqs. and use for removal of oligosaccharides from
       glycoprotein)
IT
     7732-18-5, Water, uses
     RL: DEV (Device component use); USES (Uses)
        (bath; high-temperature incubation apparatus for small vols. of liqs. and
use for
        removal of oligosaccharides from glycoprotein)
     9003-07-0, Polypropylene
IT
     RL: DEV (Device component use); USES (Uses)
        (microcentrifuge tubes; high-temperature incubation apparatus for small
vols. of
        liqs. and use for removal of oligosaccharides from
        glycoprotein)
    ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
L80
     2003:777975 HCAPLUS
ΑN
DN
     139:287260
ED
    Entered STN: 03 Oct 2003
    Methods for purification of oligonucleotides methods for
     oligonucleotides using anion exchange chromatography
```

```
Johansen, Jack T.
TN
    Avecia Biotechnology Inc., USA; Avecia Limited
PA
so ·
    PCT Int. Appl., 20 pp.
    CODEN: PIXXD2
DT
    Patent
LA
    English
IC
     ICM C12N015-10
     3-1 (Biochemical Genetics)
CC
    Section cross-reference(s): 9
FAN.CNT 1
                      KIND DATE
                                         APPLICATION NO.
                                                                DATE
    PATENT NO.
                              -----
                                         ------
                       ----
    WO 2003080834 A2
WO 2003080834 A3
                              20031002 WO 2003-GB1161
                                                                20030319
PΙ
                               20031231
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-367060P
                        P
                               20020321
CLASS
              CLASS PATENT FAMILY CLASSIFICATION CODES
PATENT NO.
 _____
WO 2003080834 ICM C12N015-10
    The present invention discloses methods for separating oligonucleotides
     from impurities. In the methods of the invention, a target
     oligonucleotide, in a mixture comprising the target
     oligonucleotide and an impurity, is separated from the impurity using
     a titratable anion exchange composition The target oligonucleotide
     is bound to the titratable anion exchange composition and an eluting solution
    which increases in pH over time is passed through the titratable anion
     exchange composition with the target oligonucleotide bound thereon.
     Preferably, the eluting solution does not substantially increase its salt
     concentration The target oligonucleotide is eluted and thereby separated
     from the impurity which either elutes at a lower pH or a higher pH than
     the target oligonucleotide.
st
    oligonucleotide purifn anion exchange chromatog
IT
    Oligonucleotides
    RL: PUR (Purification or recovery); PREP (Preparation)
        (5'-0-trityl or 5'-0-dimethoxy-trityl protected; methods for purification of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
     Salts, biological studies
IT
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (absent in oligonucleotide solution; methods for purification of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
    Polymers, uses
IT
      Polysaccharides, uses
    RL: DEV (Device component use); USES (Uses)
        (anion exchange chromatog. support; methods for purification of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
IT
    рН
       (effects of oligonucleotide elution; methods for purification of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
    Anion exchange chromatography
IT
```

```
(methods for purification of oligonucleotides methods for
       oligonucleotides using anion exchange chromatog.)
    Phosphorothioate oligodeoxyribonucleotides
IT
    RL: PUR (Purification or recovery); PREP (Preparation)
        (methods for purification of oligonucleotides methods for
       oligonucleotides using anion exchange chromatog.)
    Oligodeoxyribonucleotides
TT
    RL: PUR (Purification or recovery); PREP (Preparation)
        (phosphoramidate-linked; methods for purification of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
    Silica gel, uses
IT
    RL: DEV (Device component use); USES (Uses)
        (polyethyleneimine derivatized, anion exchange chromatog. support;
       methods for purification of oligonucleotides methods for
       oligonucleotides using anion exchange chromatog.)
ΙT
    Amines, uses
    RL: DEV (Device component use); USES (Uses)
        (primary, anion exchange chromatog. matrix comprising; methods for
       purification of oligonucleotides methods for
       oligonucleotides using anion exchange chromatog.)
IT
    Amines, uses
    RL: DEV (Device component use); USES (Uses)
        (secondary, anion exchange chromatog. matrix comprising; methods for
       purification of oligonucleotides methods for
       oligonucleotides using anion exchange chromatog.)
TΤ
    Amines, uses
    RL: DEV (Device component use); USES (Uses)
        (tertiary, anion exchange chromatog. matrix comprising; methods for
       purification of oligonucleotides methods for
       oligonucleotides using anion exchange chromatog.)
     9002-98-6D, silica gel derivative, styrene divinyl benzene copolymer
TT
     25104-18-1, Polylysine
                             26062-48-6, Polyhistidine 82370-43-2,
     Polyimidazole
    RL: DEV (Device component use); USES (Uses)
        (anion exchange chromatog, matrix comprising; methods for purification of
        oligonucleotides methods for oligonucleotides using
        anion exchange chromatog.)
                             9003-01-4, Polyacrylic acid
     9002-88-4, Polyethylene
                    9003-70-7D, Styrene divinyl benzene copolymer,
     Polypropylene
    polyethyleneimine-derivatized 9012-36-6, Agarose
    RL: DEV (Device component use); USES (Uses)
        (anion exchange chromatog. support; methods for purification of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
     993-13-5D, oligodeoxyribonucleotides derivs.
IT
     Phosphorodithioate, oligonucleotide conjugates
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (methods for purification of oligonucleotides methods for
        oligonucleotides using anion exchange chromatog.)
     1066-33-7, Ammonium bicarbonate
IT
     1336-21-6, Ammonium hydroxide
     RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (oligodeoxyribonucleotides in solution comprising; methods for purification
of
        oligonucleotides methods for oligonucleotides using
        anion exchange chromatog.)
IT
     607752-17-0
     RL: PRP (Properties)
        (unclaimed nucleotide sequence; methods for purification of
        oligonucleotides methods for oligonucleotides using
        anion exchange chromatog.)
```

```
1066-33-7, Ammonium bicarbonate
TΤ
     1336-21-6, Ammonium hydroxide
    RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (oligodeoxyribonucleotides in solution comprising; methods for purification
of
       oligonucleotides methods for oligonucleotides using
       anion exchange chromatog.)
     1066-33-7 HCAPLUS
RN
    Carbonic acid, monoammonium salt (8CI, 9CI) (CA INDEX NAME)
CN
HO-C-OH
 ● инз
    1336-21-6 HCAPLUS
RN
    Ammonium hydroxide ((NH4)(OH)) (9CI) (CA INDEX NAME)
CN
H4N-OH
    ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
L80
     2002:676205 HCAPLUS
ΑN
DN
     137:212867
    Entered STN: 08 Sep 2002
ED
    N-acetylqlucosaminyltransferase II fusion protein with
TT
     carbohydrate-binding protein and application for enzymatic
     synthesis of complex oligosaccharides
     Fujiyama, Kazuhito; Seki, Tatsuji; Nishimura, Shinichiro; Nakagawa,
IN
     Hiroaki; Nishiguchi, Susumu
     Toyo Boseki Kabushiki Kaisha, Japan
PA
so
     PCT Int. Appl., 97 pp.
     CODEN: PIXXD2
DT
     Patent
LΑ
     Japanese
IC
     ICM C12N015-62
         C12N015-54; C12N009-10; C12N001-15; C12N001-19; C12N001-21;
         C12N005-10; C12P019-04
CC
     7-8 (Enzymes)
     Section cross-reference(s): 3, 16
FAN.CNT 1
                        KIND
                               DATE
                                           APPLICATION NO.
                                                                  DATE
    PATENT NO.
                                            -----
                                                                   -----
                         _ _ _ _
                                                                   20020226
                                20020906
                                           WO 2002-JP1695
PΙ
    WO 2002068661
                         A1
        W: JP, US
        RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE, TR
                                20031217
                                           EP 2002-700768
                                                                   20020226
     EP 1371732
                         Α1
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY, TR
    US 2004110176
                         A1
                                20040610
                                           US 2003-469145
                                                                   20031112
PRAI JP 2001-49955
                         Α
                                20010226
     JP 2001-250165
                         Α
                                20010821
    WO 2002-JP1695
                         W
                                20020226
```

CLASS

```
CLASS PATENT FAMILY CLASSIFICATION CODES
 PATENT NO.
                 ICM
WO 2002068661
                        C12N015-62
                 ICS
                        C12N015-54; C12N009-10; C12N001-15; C12N001-19;
                        C12N001-21; C12N005-10; C12P019-04
EP 1371732
                 ECLA
                        C12N009/10D1
US 2004110176 ECLA
                        C12N009/10D1
     A fusion protein of UDP-GlcNAc: \alpha-6-D-mannoside \beta-1,2-N-
     acetylglucosaminyltransferase II (GnT II; EC 2.4.1.143) with a
     carbohydrate-binding protein, recombinant expression, purification, and
     use in enzymic synthesis of complex oligosaccharides, are
     disclosed. A carbohydrate-binding protein can be attached to
     GnT II via a linker containing a protease recognition site for separation by
     protease cleavage. Glycoprotein sugar
     chains can be converted to complex oligosaccharides via
     treatment with a glycosidase, UDP-GlcNAc and \beta-1,2-N-
     acetylglucosaminyltransferase I (GnT I), \alpha-mannosidase, UDP-GlcNAc
     and GnT II, and a glycosyltransferase. The authors developed a
     large-scale preparation system for recombinant human GnT II (hGnT II) using the
     maltose binding protein (MBP) fusion system to facilitate the chemoenzymic
     route for complex-type N-linked glycan synthesis. MBP-fused GnT II was
     expressed in Escherichia coli cells and purified by affinity chromatog. on
     an amylose resin column. MBP-fused GnT II exhibited optimal activity at
     pH 6.5-9.0 and was more active between pH 6.5-9.0. The optimum temperature for
     MBP-fused GnT II activity was 30-40°, but the enzyme was stable
     below 40°. Mn2+ and Co2+ were critical for the enzyme activity, while
     Zn2+ and Ca2+ inhibited the activity. Immobilization of MBP-fused GnT II
     on the amylose resin led to an 80% yield of the high mannose-type-of
     oligosaccharide. MBP-hGnT II showed activity toward pyridylamino
     oligosaccharides (2 and 6). RNaseB sugar chain was
     converted to a high-mannose-type N-linked oligosaccharide (3)
     via treatment with \alpha1,2-mannosidase, MBP-hGnT I, Jackbean
     \alpha-mannosidase or mouse \alpha-mannosidase II, and MBP-hGnT II.
     Conversion of RNaseB high-mannose-type N-linked oligosaccharide
     to a complex carbohydrate (oligosaccharide) (17) via
     treatment with immobilized \alpha 1, 2-mannosidase, GnT I,
     \alpha-mannosidase, GnT II. \beta1,4-galactosyltransferase, and
     \alpha2,6-sialyltransferase.
     N acetylqlucosaminyltransferase II fusion carbohydrate binding
ST
     protein; enzymic oligosaccharide synthesis MBP hGnT II fusion
IT
     Human
        (GnT II of; N-acetylglucosaminyltransferase II fusion protein with
        carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
IT
     Proteins
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (MBP (maltose-binding protein), fusion products; N-
        acetylqlucosaminyltransferase II fusion protein with
        carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
IT
     Molecular cloning
     Protein sequences
     cDNA sequences
        (N-acetylglucosaminyltransferase II fusion protein with
        carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
IT
     Glycoproteins
     RL: BCP (Biochemical process); BIOL (Biological study);
     PROC (Process)
        (N-acetylglucosaminyltransferase II fusion protein with
        carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
```

```
Mannooligosaccharides
    RL: BCP (Biochemical process); BPN (Biosynthetic preparation);
    BIOL (Biological study); PREP (Preparation); PROC (Process)
        (N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
TТ
    Carbohydrates, preparation
    RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP
     (Preparation)
        (N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
    Fusion proteins (chimeric proteins)
    RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties);
    PUR (Purification or recovery); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
TT
    Oligosaccharides, preparation
    RL: BCP (Biochemical process); BPN (Biosynthetic preparation);
    BIOL (Biological study); PREP (Preparation); PROC (Process)
        (N-linked; N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
IT
    Proteins
    RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (carbohydrate-binding; N-acetylglucosaminyltransferase II
       fusion protein with carbohydrate-binding protein and
       application for enzymic synthesis of complex oligosaccharides
IT
    Cations
        (divalent, fusion protein isolation in the presence of;
       N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
     Immobilization, molecular or cellular
IT
        (enzyme; N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
ΙT
    Escherichia coli
        (recombinant expression in; N-acetylglucosaminyltransferase II fusion
       protein with carbohydrate-binding protein and application for
       enzymic synthesis of complex oligosaccharides)
IT
    Affinity chromatography
        (use in purification; N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
     105913-04-0P, β1,2-N-Acetylglucosaminyltransferase II
IT
    RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties);
    PUR (Purification or recovery); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
               2956-16-3, UDP-Gal
IT
    528-04-1
    RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
     9001-34-7, Galactosidase 9001-67-6, Sialidase 9025-42-7,
IT
```

```
9027-56-9, N-Acetylglucosaminidase
                                                          9031-68-9,
    α-Mannosidase
    Galactosyltransferase 9032-92-2, Glycosidase 9033-07-2,
                         9054-49-3, N-Acetylglucosaminyltransferase
    Glycosyltransferase
     9075-81-4, α2,6-Sialyltransferase 37211-66-8, Mannosidase
    37237-43-7, β1,4-Galactosyltransferase 56626-18-7,
    Fucosyltransferase 82047-77-6, \alpha-Mannosidase II
                                                         102576-81-8,
    Acetylglucosaminyltransferase I
                                     111070-05-4, Fucosidase
                                                                125858-89-1,
                 321976-25-4, Sialyltransferase
    Xylosidase
    RL: BUU (Biological use, unclassified); CAT (Catalyst use); BIOL
     (Biological study); USES (Uses)
        (N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
     456527-84-7
IT
    RL: PRP (Properties)
        (Unclaimed; N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
IT
     456531-43-4P
    RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties);
     PUR (Purification or recovery); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (amino acid sequence; N-acetylglucosaminyltransferase II fusion protein
       with carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
ΙT
     7439-96-5, Manganese, biological studies
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (fusion protein isolation in the presence of; N-
       acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
     456531-44-5
TТ
     RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological
     study); USES (Uses)
        (nucleotide sequence; N-acetylglucosaminyltransferase II fusion protein
       with carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
     141618-93-1
IT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (product of conversion of 2; N-acetylglucosaminyltransferase II fusion
       protein with carbohydrate-binding protein and application for
        enzymic synthesis of complex oligosaccharides)
                                              457069-69-1
ΙT
     106915-90-6
                 456527-87-0
                               456527-88-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (product; N-acetylglucosaminyltransferase II fusion protein with
        carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
IT
     456527-85-8
                  456527-86-9
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (substrate; N-acetylglucosaminyltransferase II fusion protein with
        carbohydrate-binding protein and application for enzymic
        synthesis of complex oligosaccharides)
                                                             456535-57-2
                                               456535-56-1
TΤ
     456535-53-8
                 456535-54-9
                                 456535-55-0
     RL: PRP (Properties)
        (unclaimed nucleotide sequence; n-acetylglucosaminyltransferase II
        fusion protein with carbohydrate-binding protein and
        application for enzymic synthesis of complex oligosaccharides
IT
     91859-00-6
     RL: PRP (Properties)
        (unclaimed sequence; n-acetylglucosaminyltransferase II fusion protein
       with carbohydrate-binding protein and application for enzymic
```

```
synthesis of complex oligosaccharides)
     9001-92-7, Proteinase 9002-05-5, Blood coagulation factor Xa
IT
     RL: BUU (Biological use, unclassified); CAT (Catalyst use); BIOL
     (Biological study); USES (Uses)
        (use in MBP cleavage from fusion protein;
       N-acetylglucosaminyltransferase II fusion protein with
       carbohydrate-binding protein and application for enzymic
       synthesis of complex oligosaccharides)
TT
     87110-44-9
    RL: BUU (Biological use, unclassified); CAT (Catalyst use); BIOL
     (Biological study); USES (Uses)
        (α1,2-Mannosidase; N-acetylglucosaminyltransferase II fusion
       protein with carbohydrate-binding protein and application for
       enzymic synthesis of complex oligosaccharides)
             THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
RE
(1) Reck, F; Carbohydr Res 1994, V259, P93 HCAPLUS
(2) Reck, F; Carbohydr Res 1995, V275, P221 HCAPLUS
(3) Schachter, H; Glycobiology 1991, V1(5), P453 HCAPLUS
(4) Tan, J; Eur J Biochem 1995, V231, P317 HCAPLUS
(5) Weller, U; Eur J Biochem 1996, V236, P34 HCAPLUS
    ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
L80
    2002:72110 HCAPLUS
AN
     136:115133
DN
    Entered STN: 25 Jan 2002
ED
    The recovery of oxygen linked oligosaccharides from mammal
TΙ
     glycoproteins
IN
    Packer, Nicolle Hannah; Karlsson, Niclas
PΑ
    Proteome Systems Ltd, Australia
SO
    PCT Int. Appl., 37 pp.
    CODEN: PIXXD2
DT
    Patent
LΑ
    English
    ICM C07H001-08
IC
CC
    9-16 (Biochemical Methods)
FAN.CNT 1
                                         APPLICATION NO.
    PATENT NO.
                                                               DATE
                        KIND
                              DATE
                              -----
                                          -----
                        ----
    WO 2002006295
                        A1
                              20020124 WO 2001-AU871
                                                                 20010718
PΤ
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
            UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                            20030416 EP 2001-951234
    EP 1301521
                                                               20010718
                        A1
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                         US 2003-333541
    US 2004039192
                               20040226
                                                               20030728
                        A1
PRAI AU 2000-8854
                         Α
                               20000718
    WO 2001-AU871
                               20010718
                         W
CLASS
 PATENT NO.
                CLASS PATENT FAMILY CLASSIFICATION CODES
                       _____
 -----
WO 2002006295 ICM
                       C07H001-08
US 2004039192 ECLA
                       C07H001/08
    The present invention provides a method of recovering O-linked
    oligosaccharides from a macromol., the method comprising the
```

steps: exposing the macromol. to an alkaline agent to release O-linked

```
olisaccharides from the macromol.; separating the released
     oligosaccharide from the macromol.; and recovering the
     oligosaccharide.
     recovery oxygen linked oligosaccharide mammal
ST
     glycoprotein
IT
     Solutions
        (Alkaline; recovery of oxygen linked oligosaccharides from mammal
        glycoproteins)
IT
     Mucins
     RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological
     study); RACT (Reactant or reagent)
        (Gastric; recovery of oxygen linked oligosaccharides from
        mammal glycoproteins)
IT 
     Oligosaccharides, preparation
     RL: PUR (Purification or recovery); PREP (Preparation)
        (O-linked; recovery of oxygen linked oligosaccharides from
        mammal glycoproteins)
TΤ
     Mucins
     RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological
     study); RACT (Reactant or reagent)
        (Submaxillary; recovery of oxygen linked oligosaccharides
        from mammal glycoproteins)
IT
     Spheres
        (beads, Reverse phase chromatog.; recovery of oxygen linked
        oligosaccharides from mammal glycoproteins)
IT
     Reversed phase chromatography
        (beads; recovery of oxygen linked oligosaccharides from
        mammal glycoproteins)
TT
     Cation exchangers
     Cation exchangers
     Columns and Towers
     Concentration (condition)
     Immobilization, molecular or cellular
     Mammalia
     Membranes, nonbiological
     Neutralization
     Pumps
     Separation
        (recovery of oxygen linked oligosaccharides from mammal
        glycoproteins)
ΙT
     Fetuins
       Glycoproteins
       Glycoproteins
     Macromolecular compounds
     RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL
     (Biological study); RACT (Reactant or reagent)
        (recovery of oxygen linked oligosaccharides from mammal
        glycoproteins)
IT
     Acids, uses
     RL: NUU (Other use, unclassified); USES (Uses)
        (recovery of oxygen linked oligosaccharides from mammal
        glycoproteins)
IT
     Alkali metal hydroxides
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (recovery of oxygen linked oligosaccharides from mammal
        glycoproteins)
     Cation exchange chromatography
IT
        (stationary phases; recovery of oxygen linked oligosaccharides
        from mammal glycoproteins)
IT
     Elimination reaction
        (\beta -; recovery of oxygen linked oligosaccharides
        from mammal glycoproteins)
```

7647-01-0, Hydrochloric acid, uses 7782-42-5, Graphite, uses

ΙT

maier - 10 / 643502 RL: NUU (Other use, unclassified); USES (Uses) (recovery of oxygen linked oligosaccharides from mammal glycoproteins) 1310-58-3, Potassium hydroxide, reactions 1310-73-2, Sodium hydroxide, TT reactions 1336-21-6, Ammonium hydroxide RL: RCT (Reactant); RACT (Reactant or reagent) (recovery of oxygen linked oligosaccharides from mammal glycoproteins) THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT RE (1) Aeed, P; Glycoconjugate Journal 1998, V15(10), P975 HCAPLUS (2) Brockhausen, I; Canadian Journal of Biochemistry and Cell Biology 1984, V62(11), P1081 HCAPLUS (3) Capon, C; European Journal of Biochemistry 1989, V182(1), P139 HCAPLUS (4) Carlson, D; The Journal of Biological Chemistry 1966, V241(5), P2984 (5) Chandrasekaran, E; Cancer Research 1984, V44, P1557 HCAPLUS (6) Ensogutzeit Oy; WO 8504409 A 1985 HCAPLUS (7) Jean-Richard, N; Carbohydrate Research 1985, V138, P189 (8) Jikibara, T; Journal of Biochemistry 1992, V111, P236 HCAPLUS (9) Natl Food Res Inst And Nisshin Flour Milling Co Ltd; JP 04053496 A 1992 **HCAPLUS** (10) Oji Koonsutaac Kk And Oji Paper Co Ltd; JP 63007775 A 1988 (11) Patel, T; Biochemistry 1993, V32(2), P679 HCAPLUS (12) Rana, S; The Journal of Biological Chemistry 1984, V259, P12899 HCAPLUS (13) Slovenska Technicka Univerzita; WO 9312243 A 1993 HCAPLUS IT 1336-21-6, Ammonium hydroxide RL: RCT (Reactant); RACT (Reactant or reagent) (recovery of oxygen linked oligosaccharides from mammal glycoproteins) RN1336-21-6 HCAPLUS CN Ammonium hydroxide ((NH4)(OH)) (9CI) (CA INDEX NAME) H_4N-OH ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN L80 2000:514685 HCAPLUS ANDN 133:248650 Entered STN: 30 Jul 2000 ED Structure of a major oligosaccharide of PASII/PMP22 TIglycoprotein in bovine peripheral nerve myelin Kitamura, Kunio; Uyemura, Keiichi; Shibuya, Kyoko; Sakamoto, Yasushi; ΑU Yoshimura, Kazunori; Nomura, Masahiko Department of Physiology, Saitama Medical School, Saitama, 350-0495, Japan CS Journal of Neurochemistry (2000), 75(2), 853-860 SO CODEN: JONRA9; ISSN: 0022-3042 PB Lippincott Williams & Wilkins DT Journal LĄ English CC 6-4 (General Biochemistry) AB The amino acid sequence of the glycopeptide obtained from bovine PASII/PMP22 protein in the PNS myelin was determined to be Gln-Asn-Cys-Ser-Thr, where the asparagine was glycosylated. To eliminate all the contaminated PO glycopeptides from the PASII/PMP22 glycopeptide preparation, we used a fluorescent probe, N-[2-(2-pyridylamino)ethyl]maleimide, which reacts with the cysteine of the PASII/PMP22 glycopeptides. The labeled PASII/PMP22 glycopeptides were isolated by HPLC and were digested further

with glycopeptidase A. The resultant oligosaccharides were

oligosaccharide, OPPE1, was purified by HPLC. The structure of

conjugated with 2-aminopyridine (PA) as a fluorescent tag. One major PA-

OPPE1 was elucidated by fast atom bombardment mass spectrometry and 1H-NMR

```
studies and comparing the derivs. of PAOPPE1 and PA-
     oligosaccharides of \gamma-globulin on HPLC. The structure,
     SO4-3GlcAβ 1-3Galβ 1-4GlcNAc.beta
     .1-2Man\alpha1-6 (GlcNAc \beta 1-4) (GlcNAc.beta
     .1-2Manα1-3)Man β 1-4GlcNAc.beta
     .1-4(Fucα1-6)GlcNAc-PA, was identical to the pyridylaminated form of
     the major oligosaccharide D8 of bovine P0 previously reported.
ST
     oligosaccharide OPPE1 structure PASII PMP22 glycoprotein
    mvelin
IΤ
     Oligosaccharides, properties
     RL: PRP (Properties); PUR (Purification or recovery); PREP
     (Preparation)
        (OPPE1 of PASII/PMP22 glycoprotein; structure of a major
        oligosaccharide of PASII/PMP22 glycoprotein in bovine
        peripheral nerve myelin)
     Glycoproteins, specific or class
TΤ
     RL: BPR (Biological process); BSU (Biological study,
     unclassified); PRP (Properties); BIOL (Biological study); PROC
     (Process)
        (PASII/PMP22; structure of a major oligosaccharide of
        PASII/PMP22 glycoprotein in bovine peripheral nerve myelin)
IT
    Myelin
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (bovine peripheral nerve; structure of a major oligosaccharide
        of PASII/PMP22 glycoprotein in bovine peripheral nerve
        myelin)
     294869-15-1P
IT
     RL: PRP (Properties); PUR (Purification or recovery); PREP (Preparation)
        (OPPE1; structure of a major oligosaccharide of PASII/PMP22
        glycoprotein in bovine peripheral nerve myelin)
              THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
RE
(1) Abo, T; J Immunol 1981, V127, P1024 MEDLINE
(2) Ariga, T; J Biol Chem 1987, V262, P848 HCAPLUS
(3) Baumann, N; Ann NY Acad Sci 1998, V845, P322 HCAPLUS
(4) Bollensen, E; Neurology 1988, V38, P81266
(5) Bollensen, E; Neurosci Lett 1987, V82, P177
(6) Ellie, E; J Neurol 1996, V243, P34 MEDLINE
(7) Filbin, M; J Cell Biol 1993, V122, P451 HCAPLUS
(8) Filbin, M; Nature 1990, V344, P871 HCAPLUS
(9) Filbin, M; Neuron 1991, V7, P845 HCAPLUS
(10) Griffiths, I; Microsc Res Tech 1998, V41, P344 HCAPLUS
(11) Hammer, J; J Neurosci Res 1993, V35, P546 HCAPLUS
(12) Johns, T; J Neurochem 1999, V72, P1 HCAPLUS
(13) Kitamura, K; Biochim Biophys Acta 1976, V455, P806 HCAPLUS
(14) Kitamura, K; Biomed Res 1981, V2, P347 HCAPLUS
(15) Kitamura, K; FEBS Lett 1979, V100, P67 HCAPLUS
(16) Kitamura, K; Glycoconjugates 1981, P273
(17) Kitamura, K; J Neurochem 1995, V65(Suppl), PS108B
(18) Nagasawa, K; Carbohydr Res 1977, V58, P47 HCAPLUS
(19) Sakamoto, Y; Biochim Biophys Acta 1995, V1252, P209 HCAPLUS(20) Sakamoto, Y; J Biol Chem 1987, V262, P4208 HCAPLUS
(21) Schnaar, R; Ann NY Acad Sci 1998, V845, P92 HCAPLUS
(22) Snipes, G; J Cell Biol 1992, V117, P1225
(23) Snipes, G; J Neurochem 1993, V61, P1961 HCAPLUS
(24) Takahashi, N; Biochemistry 1987, V26, P1137 HCAPLUS
(25) Uyemura, K; Myelin: Biology and Chemistry 1992, P481 HCAPLUS
(26) Uyemura, K; Neurosci Res 1993, V16, P9 HCAPLUS
(27) Vliegenthart, J; Adv Carbohydr Chem Biochem 1983, V41, P209 HCAPLUS
(28) Voshol, H; J Biol Chem 1996, V271, P22957 HCAPLUS
(29) Weiss, M; J Neuroimmunol 1999, V95, P174 HCAPLUS
```

(30) Yazaki, T; FEBS Lett 1992, V307, P361 HCAPLUS

```
(31) Yu, R; Ann NY Acad Sci 1998, V845, P285 HCAPLUS
     ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
L80
     2000:87596 HCAPLUS
AN
     132:331569
DN
     Entered STN: 07 Feb 2000
ED
     Selective Organic Precipitation/Extraction of Released N-Glycans Following
TΙ
     Large-Scale Enzymatic Deglycosylation of Glycoproteins
     Verostek, Mary Frances; Lubowski, Catherine; Trimble, Robert B.
ΑIJ
     Wadsworth Center, New York State Department of Health, Albany, NY,
CS
     12201-0509, USA
     Analytical Biochemistry (2000), 278(2), 111-122
SO
     CODEN: ANBCA2; ISSN: 0003-2697
     Academic Press
PB
DT
     Journal
     English
LA
     9-9 (Biochemical Methods)
CC
     A major difficulty with isolating enzymically or chemical released
AB
     oligosaccharides from large-scale glycoprotein
     dealycosylation reactions is the time-consuming chromatog., desalting, and
     concentration steps required to prepare a glycan fraction of manageable
     proportions. To overcome these time and preparative chromatog. equipment
     requirements, we have developed a rapid organic solvent
precipitation/extraction procedure
     that allows sequential isolation of endo-.beta
      .-N-acetylglucosaminidase H (EC 3.2.1.96)-released high-mannose and
     hybrid, peptide-N4-(N-acetyl-\beta-glucosaminyl) Asn amidase
      (EC 3.5.1.52)-released complex, and \beta -eliminated
     O-linked glycans without the need for intermediate chromatog., desalting,
     or concentration steps. The method involves precipitation of protein and
released
     glycans at -20° in 80% acetone and extraction of the glycans from the
     pellet with 60% aqueous methanol after each deglycosylation step. Three pools
      of essentially salt- and detergent-free oligosaccharides
      (high-mannose/hybrid, complex, and O-linked) can be isolated in a high
      yield in 4 days with this protocol, which has been extensively tested
      using bovine RNase B, human bile salt-stimulated lipase expressed in
      Pichia pastoris, hen ovalbumin, bovine fetuin, bovine thyroglobulin, and
      several invertase prepns. from wild-type and mutant yeast strains.
      2000 Academic Press.
      org pptn extn glycan enzymic deglycosylation glycoprotein
 ST
      Oligosaccharides, preparation
 IT
        Polysaccharides, preparation
      RL: PEP (Physical, engineering or chemical process); PUR
      (Purification or recovery); PREP (Preparation); PROC
      (Process)
         (N-; selective organic precipitation/extraction of released N-glycans
 following
         large-scale enzymic deglycosylation of glycoproteins)
 IT
      Glycosylation
         (deglycosylation, Enzymic; selective organic precipitation/extraction of
 released
        N-qlycans following large-scale enzymic deglycosylation of
         glycoproteins)
      Solvents
         (organic; selective organic precipitation/extraction of released N-glycans
 following
         large-scale enzymic deglycosylation of glycoproteins)
 IT
      Extraction
      Komagataella pastoris
      Precipitation (chemical)
```

(selective organic precipitation/extraction of released N-glycans following

large-scale

```
enzymic deglycosylation of glycoproteins)
IT
     Proteins, general, processes
     RL: PEP (Physical, engineering or chemical process); PROC (Process)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
IT
     Fetuins
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
     Glycoproteins, general, reactions
IT
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
IT
     Ovalbumin
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
IT
     Thyroglobulin
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
     Elimination reaction
        (β -; selective organic precipitation/extraction of released N-glycans
        following large-scale enzymic deglycosylation of glycoproteins
IT
     9001-99-4
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (B, bovine; selective organic precipitation/extraction of released
N-qlycans following
        large-scale enzymic deglycosylation of glycoproteins)
     9001-62-1, Lipase
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (Bile salt-stimulated; selective organic precipitation/extraction of
released N-glycans
        following large-scale enzymic deglycosylation of glycoproteins
IT
     3458-28-4, D-Mannose
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
     37278-88-9, endo-β-N-Acetylglucosaminidase H
                                                     83534-39-8,
     Peptide-N4-N-Acetyl-β-glucosaminyl asparagine amidase
     RL: CAT (Catalyst use); USES (Uses)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
     67-56-1, Methanol, uses 67-64-1, Acetone, uses
     RL: NUU (Other use, unclassified); USES (Uses)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
     9001-57-4, Invertase
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (selective organic precipitation/extraction of released N-glycans following
large-scale
        enzymic deglycosylation of glycoproteins)
              THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 43
```

```
(1) Alvarado, E; Biochemistry 1990, V29, P2471 HCAPLUS
(2) Aminoff, D; Biochem J 1961, V81, P384 HCAPLUS
(3) Arima, T; J Biol Chem 1972, V247, P1825 HCAPLUS
(4) Arima, T; J Biol Chem 1972, V247, P1836 HCAPLUS
(5) Bearden, J; Biochim Biophys Acta 1978, V533, P525 HCAPLUS
(6) Brockhausen, I; New Comprehensive Biochemistry 1995, V29a, P201 HCAPLUS
(7) Byrd, J; J Biol Chem 1982, V257, P14657 HCAPLUS
(8) Chu, F; Biochemistry 1978, V253, P8691 HCAPLUS
(9) Dubois, M; Anal Chem 1956, V28, P350 HCAPLUS
(10) Esmon, B; J Biol Chem 1984, V259, P10322 HCAPLUS
(11) Goldstein, A; Methods Enzymol 1975, V42, P504 MEDLINE
(12) Hager, D; Anal Biochem 1980, V109, P76 HCAPLUS
(13) Haselbeck, A; Anal Biochem 1990, V191, P25 HCAPLUS
(14) Herscovicz, A; FASEB J 1993, V7, P540
(15) Huang, C; Carbohydr Res 1972, V22, P83 HCAPLUS
(16) Ito, S; J Biochem 1977, V81, P1621 HCAPLUS
(17) Kornfeld, R; Annu Rev Biochem 1985, V54, P631 MEDLINE
(18) Kukuruzinska, M; Annu Rev Biochem 1987, V56, P915 HCAPLUS
(19) Laemmli, U; Nature (London) 1970, V227, P680 HCAPLUS
(20) Liang, C; J Biochem 1980, V88, P51 HCAPLUS
(21) Nakajima, T; Proc Natl Acad Sci USA 1975, V72, P3912 HCAPLUS
(22) Neumann, N; Biochemistry 1967, V6, P468 HCAPLUS
(23) Ozols, J; Methods Enzymol 1990, V182, P587 HCAPLUS
(24) Reddy, V; J Biol Chem 1988, V263, P6978 HCAPLUS
(25) Skoza, L; Biochem J 1976, V159, P457 HCAPLUS
(26) Spiro, R; J Biol Chem 1962, V237, P382 HCAPLUS
(27) Spiro, R; J Biol Chem 1974, V249, P5704 HCAPLUS
(28) Stromqvist, M; J Chromatogr A 1995, V718, P53 MEDLINE
(29) Suzuki, H; Anal Biochem 1988, V172, P259 HCAPLUS
(30) Tarentino, A; J Biol Chem 1970, V245, P4150 HCAPLUS
(31) Tarentino, A; Methods Cell Biol 1989, V32, P111 HCAPLUS
(32) Trimble, R; J Biol Chem 1977, V252, P4409 HCAPLUS
(33) Trimble, R; J Biol Chem 1980, V255, P10232 HCAPLUS
(34) Trimble, R; J Biol Chem 1986, V261, P9815 HCAPLUS
(35) Trimble, R; J Biol Chem 1991, V266, P1646 HCAPLUS
(36) Trimble, R; Trends Glycosci Glycotechnol 1995, V1(33), P1
(37) Trumbly, R; J Biol Chem 1985, V260, P5683 HCAPLUS
(38) Verostek, M; J Biol Chem 1993, V268, P12095 HCAPLUS
(39) Verostek, M; J Biol Chem 1993, V268, P12104 HCAPLUS
(40) Yamamoto, K; Biochem J 1981, V195, P701 HCAPLUS
(41) Zeng, C; J Mass Spectrom 1999, V34, P311 HCAPLUS
(42) Ziegler, F; Glycobiology 1999, V9, P497 HCAPLUS
(43) Ziegler, F; J Biol Chem 1988, V263, P6986 HCAPLUS
    ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
L80
ΑN
     1995:712088 HCAPLUS
     123:137433
DN
ED
     Entered STN: 01 Aug 1995
     Isolation and characterization of glycosidases from Xanthomonas and their
TI
     use in selective cleavage of carbohydrates
     Wong-Madden, Sharon Teresa; Guthrie, Ellen Paul; Landry, David; Taron,
IN
     Christopher Henry; Guan, Chudi; Robbins, Phillips Wesley
     New England Biolabs, Inc., USA
PA
SO
     PCT Int. Appl., 99 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
IC
     ICM
         C12Q001-68
          C12P021-06; C12N009-24; C12N009-36; C12N009-38; C12N009-40;
          A01N063-00; A61K038-00
CC
     7-3 (Enzymes)
     Section cross-reference(s): 9
```

```
FAN.CNT 5
                                          APPLICATION NO.
                                                                  DATE
     PATENT NO.
                       KIND DATE
     -----
                         ----
                                            -----
                                                                    _____
     WO 9508645
                         A1
                                19950330 WO 1994-US10758
                                                                  19940922
PΤ
         W: JP, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
                                19960821
                                           EP 1994-929309
                                                                   19940922
     EP 726964
                         A1
        R: DE, FR, GB
    JP 09508783 T2
US 6300113 B1
US 5770405 A
US 6342365 B1
                                                                   19940922
                                19970909
                                           JP 1994-509944
                                20011009
                                           US 1995-560809
                                                                  19951121
                                19980623 US 1996-596250
                                                                  19960624
                                20020129 US 1999-257153
                                                                  19990224
                     B1 20021001 US 1999-428979
A1 20020613 US 2001-859698
B2 20020723
     US 6458573
                                                                  19991028
     US 2002072104
                                                                   20010517
     US 6423525
                                20020723
20020319 US 2001-883800
US 6358724
US 2002137176
PRAI US 1993-126174
US 1993-126174
US 19940922
US 6358724
US 2002137176
US 1993-126174
US 19940922
                                                                  20010618
                                20020926 US 2001-3136
                                                                  20011115
    19951121
                         A2 19960624
     US 1996-596250
                         A3 19991028
     US 1999-428979
CLASS
              CLASS PATENT FAMILY CLASSIFICATION CODES
 PATENT NO.
 ______
 WO 9508645
                        C12Q001-68
                 ICM
                        C12P021-06; C12N009-24; C12N009-36; C12N009-38;
                 ICS
                        C12N009-40; A01N063-00; A61K038-00
               ECLA
                        C12N009/24
 US 6458573
 US 2002072104 ECLA
US 2002137176 ECLA
                       C12N009/24
                        C12N009/24
     This invention is directed to compns. and methods that satisfy the need
AB
     for novel, substantially pure glycosidases having identified substrate
     specificities. Substantially pure glycosides isolated from Xanthomonas
     and recombinant glycosidases are described. Specific glycosidases which
     are described include exoglycosidase, fucosidase, galactosidase,
     N-acetylqlucosaminidase, glucosidase, xylosidase, and mannosidase.
     substrate specificity of isolated enzymes have been identified from
     GlcNac\beta-1-X, Gal\alpha-1-3R, Gal\alpha-1-6R, Gal\beta-1-3R,
     Fuc\alpha-2R, Fuc\alpha-1-3R, Fuc\alpha-1-4R, Man\alpha-1-2R,
     Man\alpha-1-3R, Man\alpha-1-6R, Man\beta-1-4R, Xyl\beta-1-2R and
     Glcβ-1-4R, where X is an unspecified C atom on an adjacent
     unspecified monosaccharide and R is the unspecified
     monosaccharide occurring within an oligosaccharide.
     These enzymes provide improved capability for selectively cleaving
     a glycosidic linkage in a carbohydrate substrate and for forming
     modified carbohydrates.
     Xanthomonas glycosidase isolation carbohydrate specificity
ST
IT
     Molecular cloning
        (cloning and expression of Xanthomonas exoglycosidase gene in
        Escherichia coli)
IT
     Gene, microbial
     RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
     BIOL (Biological study); OCCU (Occurrence)
        (cloning and expression of Xanthomonas exoglycosidase gene in
        Escherichia coli)
TT
     Oligosaccharides
     RL: ARG (Analytical reagent use); SPN (Synthetic preparation);
     ANST (Analytical study); PREP (Preparation); USES (Uses)
        (conjugates with aminocoumarin; screening of microbial glycosidases
        using fluorescent oligosaccharide substrates)
IT
     Xanthomonas
     Xanthomonas campestris holcicola
```

```
Xanthomonas campestris manihotis
    Xanthomonas campestris oryzae
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
IT
    Glycolipids
       Glycoproteins, biological studies
       Oligosaccharides
    RL: BPR (Biological process); BSU (Biological study,
    unclassified); BUU (Biological use, unclassified); BIOL (Biological
     study); PROC (Process); USES (Uses)
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
    9001-34-7, Galactosidase 9025-42-7, \alpha-Mannosidase
                                                           9033-06-1,
TΤ
                 37211-66-8, Mannosidase 52769-52-5, Exoglycosidase
    Glucosidase
                              125858-89-1, Xylosidase
     111070-05-4, Fucosidase
                                                        166433-44-9,
    \alpha-1,3-1,6 Galactosidase
    RL: BAC (Biological activity or effector, except adverse); BPR (Biological
    process); BSU (Biological study, unclassified); BUU (Biological use,
    unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
    9001-22-3P, \beta-Glucosidase 9012-33-3P, \beta-N-
TΤ
    Acetylglucosaminidase 9025-43-8P, β-Mannosidase
                                                         9032-92-2P,
                 37288-45-2P 37288-53-2P 53362-87-1P, β-Xylosidase
    Glycosidase
     82047-77-6P, α1-3,6 Mannosidase
                                       90910-03-5P
                                                     131384-39-9P
     166433-45-0P, \beta-1,3-1,4-Galactosidase
    RL: BAC (Biological activity or effector, except adverse); BPR (Biological
    process); BSU (Biological study, unclassified); BUU (Biological use,
    unclassified); PUR (Purification or recovery); BIOL (Biological study);
    PREP (Preparation); PROC (Process); USES (Uses)
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
    512-69-6 1109-28-0 3459-18-5 14116-68-8
TΤ
                                                  21973-23-9
                               38864-21-0
                                                         50722-98-0
     25541-09-7
                 33404-34-1
                                            41263-94-9
                 61652-90-2
                               66091-47-2
                                            83259-19-2
                                                         100850-25-7
     52134-33-5
     146862-59-1
    RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
     58-86-6, Xylose, biological studies
IT
    RL: BPR (Biological process); BSU (Biological study, unclassified); BUU
     (Biological use, unclassified); BIOL (Biological study); PROC (Process);
    USES (Uses)
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
     19063-57-1DP, 7-Aminocoumarin, conjugates with oligosaccharides
TT
    RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST
     (Analytical study); PREP (Preparation); USES (Uses)
        (screening of microbial glycosidases using fluorescent
       oligosaccharide substrates)
     512-69-6 1109-28-0
IT
    RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (isolation and characterization of glycosidases from Xanthomonas and
        their use in selective cleavage of carbohydrates)
    512-69-6 HCAPLUS
RN
CN
    \alpha-D-Glucopyranoside, \beta-D-fructofuranosyl O-\alpha-D-
```

Absolute stereochemistry. Rotation (+).

galactopyranosyl-(1→6)- (9CI) (CA INDEX NAME)

RN 1109-28-0 HCAPLUS CN D-Glucose, $O-\alpha$ -D-glucopyranosyl- $(1\rightarrow 4)$ - $O-\alpha$ -D-glucopyranosyl- $(1\rightarrow 4)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> => fil wpix FILE 'WPIX' ENTERED AT 14:09:36 ON 10 NOV 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE LAST UPDATED: 9 NOV 2004 <20041109/UP>
MOST RECENT DERWENT UPDATE: 200472 <200472/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

<<<

- >>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://thomsonderwent.com/coverage/latestupdates/ <<<
- >>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT: http://thomsonderwent.com/support/userguides/
- >>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX

FIRST VIEW - FILE WPIFV. FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<< >>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <>< >>> SMILES and ISOSMILES strings are no longer available as Derwent Chemistry Resource display fields => d all abeq tech abex tot ANSWER 1 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN L48 2004-447686 [42] WPIX AN DNC C2004-168032 DNN N2004-354029 Cleaving of O-linked from glycoprotein involves contacting TΙ composition comprising glycoprotein comprising O-linked oligosaccharides with a solution comprising borane-ammonia complex, and incubating the formed mixture. B04 D16 S03 DC HUANG, Y; KONSE, T; MECHREF, Y S; NOVOTNY, M V IN (HUAN-I) HUANG Y; (KONS-I) KONSE T; (MECH-I) MECHREF Y S; (NOVO-I) NOVOTNY PA M V; (ADRE-N) ADVANCED RES & TECHNOLOGY INST CYC 106 A1 20040520 (200442)* 10 C12P021-06 US 2004096933 PΙ A2 20040603 (200442) EN A61K000-00 WO 2004045502 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW C12P021-06 AU 2003285006 A1 20040615 (200470) US 2004096933 A1 Provisional US 2002-426861P 20021115, US 2003-664462 ADT 20030919; WO 2004045502 A2 WO 2003-US34088 20031024; AU 2003285006 A1 AU 2003-285006 20031024 AU 2003285006 A1 Based on WO 2004045502 20021115; US 2003-664462 20030919 PRAI US 2002-426861P ICM A61K000-00; C12P021-06 C08B037-00; C12P019-04 US2004096933 A UPAB: 20040702 AB NOVELTY - An O-linked oligosaccharide from glycoprotein is cleaved by contacting a composition comprising glycoprotein comprising O-linked oligosaccharides with a solution comprising a boraneammonia complex, incubating the formed mixture for a period of time sufficient to cleave the linked oligosaccharides from the glycoprotein; and forming a mixture comprising oligosaccharide alditol products and deglycosylated protein by-products. DETAILED DESCRIPTION - Cleaving an O-linked oligosaccharide from a glycoprotein comprises contacting a composition comprising a glycoprotein, wherein the glycoprotein comprises O-linked oligosaccharides, with a solution comprising a boraneammonia complex to form a mixture comprising the glycoprotein and the borane-ammonia complex; incubating the mixture for a period of time sufficient to cleave the linked oligosaccharides from the glycoprotein; and forming a mixture comprising oligosaccharide alditol products and deglycosylated protein

glycoprotein.

ADVANTAGE - The inventive method results in minimum sample purification and sample loss. It has enhanced capacity for structural analysis of oligosaccharides by mass spectrometric methods.

USE - For cleaving an O-linked oligosaccharide from

by-products.

Dwg.0/4 FS CPI EPI FA AB; DCN

MC CPI: B04-C02X; B04-N06; B05-B02C; B05-C01;

B11-C08A; D05-H09

EPI: S03-E10A8; S03-E14H

TECH

UPTX: 20040702

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Method: The method further comprises separating at least one cleaved oligosaccharide product from the other oligosaccharide products or from the protein by-products. The structure of oligosaccharide product and the cleaved oligosaccharide are then analyzed by mass spectrometry. The mass spectrometry method is matrix-assisted laser desorption ionization mass spectrometry and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MS). The separation is achieved using a cation exchange resin or using a hydrophobic resin. The separation may also be achieved using a cation exchange resin and a hydrophobic resin. The incubation step is performed at 20-60 (preferably 35-55) degreesC.

ABEX UPTX: 20040702

EXAMPLE - Glycoprotein samples, such as calf serum fetuin, bovine submaxillary mucin, and human milk bile salt-stimulated lipase, were prepared as aqueous solutions at 10 mg/mL concentrations. Small aliquots (e.g., 1-5 L) were transferred to a microtube and dried under nitrogen. A 10microL aliquot of the borane-ammonia complex solution was then added. The mixture was subsequently incubated at 45degreesC for 8-24 h. The reaction mixtures were then purified, and the eluent was subjected to MS analysis.

L48 ANSWER 2 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN

AN 2004-439263 [41] WPIX

DNC C2004-164513

TI Chromatographic column for separating saccharide mixtures, comprises polyfunctional polyacrylamide gel formed from a polymerizable mixture of acrylamide, bisacrylamide, filler compound, charge ligand and cyano compound.

DC A14 A25 A89 B04

IN NOVOTNY, M V; QUE, A H

PA (NOVO-I) NOVOTNY M V; (QUEA-I) QUE A H; (ADRE-N) ADVANCED RES & TECHNOLOGY INST

CYC 106

PI US 2004094481 A1 20040520 (200441)* 18 B01D015-08 WO 2004045503 A2 20040603 (200441) EN A61K000-00

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AU 2003286716 A1 20040615 (200470)

B01D015-08

ADT US 2004094481 A1 Provisional US 2002-426919P 20021115, US 2003-634058 20030804; WO 2004045503 A2 WO 2003-US34089 20031024; AU 2003286716 A1 AU 2003-286716 20031024

FDT AU 2003286716 Al Based on WO 2004045503

PRAI US 2002-426919P 20021115; US 2003-634058 20030804

IC ICM A61K000-00; B01D015-08

AB US2004094481 A UPAB: 20040629

NOVELTY - A hydrophilic, monolithic chromatographic column comprising polyfunctional polyacrylamide gel as a stationary phase, is new. The polyacrylamide gel is formed by polymerization of a monomer mixture comprising acrylamide, bisacrylamide, non-reactive filler compound for forming pores in the polyacrylamide gel, polymerizable charge ligand, and polymerizable cyano compound.

DETAILED DESCRIPTION - A hydrophilic, monolithic chromatographic column comprises polyfunctional polyacrylamide gel as a stationary phase. The polyacrylamide gel is formed by polymerization of a monomer mixture comprising acrylamide, bisacrylamide, non-reactive filler compound for forming pores in the polyacrylamide gel, polymerizable charge ligand of formula RX, and polymerizable cyano compound of formula R'CN.

X = functional group capable of maintaining a charge;

R = olefin functional group capable of free-radical propagated polymerization; and

R' = olefin functional group capable of free-radical propagated polymerization (preferably acrylate or vinyl ether).

An INDEPENDENT CLAIM is also included for a method of chromatographically separating a mixture of saccharide by introducing saccharide mixture to the above column, inducing flow of mobile phase through the column by application of electric field to produce a column effluent, and detecting separated saccharide in the column effluent.

USE - For separating mixtures of saccharides.

ADVANTAGE - The chromatographic column provides a universal system for separating a wide range of carbohydrates, mono- and oligo-saccharide with the intact reducing end, and saccharide alditol.

Dwg.0/9

FS CPI

FA AB; DCN

MC CPI: A04-B; A04-D01; A08-R01; A12-L04A; B04-C02X; B04-C03;

B07-A02; B10-A07; B11-C08D2

TECH UPTX: 20040629

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The charge ligand has a negative charge (preferably sulfonic acid) or a positive charge (preferably quaternary amine). The cyano compound is 2-cyanoethylacrylate.

TECHNOLOGY FOCUS - POLYMERS - Preferred Composition: The monomer mixture comprises charge ligand (5-40 mole%), filler compound (1-5 w/v%), cyano compound R'CN (30-40 mole%).

Preferred Components: The filler compound is polyethylene glycol having a molecular weight of 7500 - 20000.

L48 ANSWER 3 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN

AN 2004-389160 [36] WPIX

DNN N2004-309790 DNC C2004-145680

Preparation of stable oligosaccharides from glycoprotein having linked oligosaccharides, comprises contacting glycoprotein with aqueous solution of ammonium hydroxide and ammonium carbonate, and separating oligosaccharide products.

DC B04 S03

IN HUANG, Y; MECHREF, Y S; NOVOTNY, M V

PA (HUAN-I) HUANG Y; (MECH-I) MECHREF Y S; (NOVO-I) NOVOTNY M V; (ADRE-N) ADVANCED RES & TECHNOLOGY INST

CYC 106

PI US 2004096948 A1 20040520 (200436)* 13 C12P019-04 <-- WO 2004045501 A2 20040603 (200436) EN A61K000-00

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AU 2003286687 Al 20040615 (200470)

C12P019-04 <--

ADT US 2004096948 A1 Provisional US 2002-426921P 20021115, US 2003-643502 20030819; WO 2004045501 A2 WO 2003-US33888 20031024; AU 2003286687 A1 AU 2003-286687 20031024

```
FDT AU 2003286687 Al Based on WO 2004045501
                          20021115; US 2003-643502
                                                         20030819
PRAI US 2002-426921P
     ICM A61K000-00; C12P019-04
TC
     ICS C08B037-00
     US2004096948 A UPAB: 20040608
AB
     NOVELTY - A stable oligosaccharide is prepared from glycoprotein
     having linked oligosaccharides by contacting glycoprotein with
     aqueous solution of ammonium hydroxide and
     ammonium carbonate for a time to cleave linked
     oligosaccharides from glycoprotein to form oligosaccharide
     products and protein by-product; separating oligosaccharide products; and
     separating portion of the products from the protein by-product.
          USE - Used in the preparation of stable oligosaccharides from
     glycoprotein having linked oligosaccharides.
          ADVANTAGE - The invention provides a method for non-reductive
     degradation of glycoproteins with release of oligosaccharide for
     derivation and/or analysis.
     Dwq.0/6
     CPI EPI
FS
FA
     AB
     CPI: B04-C02X; B04-N04; B04-N06; B05-B02C;
MC
          B05-C01; B11-A; B11-C08; B12-K04
     EPI: S03-E14H5
                    UPTX: 20040608
TECH
     TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Methods: The
     oligosaccharide products are contacted with an aqueous acid (boric acid).
     These products are separated from the acid. The separated oligosaccharide
     products are reacted with a labeling agent to form mixture of
     oligosaccharide derivatives having common covalently bound label. A
     labeled product is separated from the other labeled product.
     ANSWER 4 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
L48
                       WPIX
AN
     2002-188534 [24]
DNC
     C2002-058268
     Recovering O-linked oligosaccharide from macromolecule comprises the step
ΤI
     of exposing the macromolecule to an alkaline agent followed by separation
     and recovery of oligosaccharide.
DC
     B04 J01
     KARLSSON, N; PACKER, N H
IN
     (PROT-N) PROTEOME SYSTEMS LTD; (KARL-I) KARLSSON N; (PACK-I) PACKER N H
PA
CYC
    97
                     A1 20020124 (200224)* EN
                                                37
                                                      C07H001-08
PΙ
     WO 2002006295
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TR TZ UG ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
            DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
            KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU
            SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
                     A 20020130 (200236)
                                                      C07H001-08
     AU 2001072217
                     A1 20030416 (200328) EN
                                                      C07H001-08
     EP 1301521
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
            RO SE SI TR
                    A1 20040226 (200416)
                                                      C08B037-00
     US 2004039192
     WO 2002006295 A1 WO 2001-AU871 20010718; AU 2001072217 A AU 2001-72217
ADT
     20010718; EP 1301521 A1 EP 2001-951234 20010718, WO 2001-AU871 20010718;
     US 2004039192 A1 WO 2001-AU871 20010718, US 2003-333541 20030728
     AU 2001072217 A Based on WO 2002006295; EP 1301521 A1 Based on WO
FDT
     2002006295
PRAI AU 2000-8854
                          20000718
     ICM C07H001-08; C08B037-00
     WO 200206295 A UPAB: 20020416
AB
     NOVELTY - Recovering O-linked oligosaccharide (A) from a macromolecule (B)
     comprises: (i) exposing (B) to an alkaline agent to release (A); (ii)
```

separating the released (A); and (iii) recovering (A).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a system for recovering (A) from (B) comprising a solid support (a) for immobilizing (B), device (b) for providing the alkaline agent to (a) device (C) for removing the alkaline agent for (a), device (d) for neutralizing the alkaline agent subsequent to its removal from (a) and device (e) for collecting (A).

USE - For removing sugar e.g. oligosaccharides from macromolecules (claimed).

ADVANTAGE - The process can be applied to all O-linked glycoproteins and is demonstrated to be successful even with the highly glycosylated mucin glycoproteins which are known to be difficult to analyze. The reducing terminal monosaccharide is still in its reducing configuration. This allows for further derivatization of the reducing end of the oligosaccharide, thus enabling methods for increasing the detectability by spectroscopic methods either by the addition to the oligosaccharide of either a chromophore, fluorophase or mass spectrometric ionizable tag.

Dwg.0/16

FS CPI

FA AB; DCN

MC CPI: B04-C02X; B05-A01A; B05-A01B; B05-C01; B05-C07;

B05-C08; B11-B; J01-D01A

TECH

UPTX: 20020416

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Process: (B) (preferably glycoprotein) is bound to (a) which is contacted with stream of the alkali agent to release (A) into the stream of alkali agent. The released (A) is separated from (B) in association with the alkaline agent and the alkaline agent is neutralized by addition of acid (preferably hydrochloric acid) or chromatography cation exchange media. (B) is exposed to the alkali agent at 45degreesC for 10 - 40 (preferably 16) hours. Preferred Components: The alkali agent (0.05 - 1.0 M) is potassium hydroxide, sodium hydroxide (0.05 - 0.5 M) or ammonium hydroxide.

Preferred Device: (a) is a chromatographic material or membrane or a column containing reverse phase chromatography beads. (b) is a pump. (d) is a column packed with cation exchange chromatography material. (e) is a column packed with graphitized carbon. The columns are placed in-line.

ABEX

UPTX: 20020416

EXAMPLE - Poros R2 (polystyrene beads coated with divinyl benzene) (10 mg) were added to a solution of sigma (bovine submaxillary mucin) (BSM) in H2O:ACN (9:1; 1 ml).

The glycoprotein-coated beads were packed into a cartridge and a solution of potassium hydroxide (0.05 M) was pumped through for 16 hours at 45degreesC at a flow rate of 0.1 ml/min.

The eluent from the reversed phase beads was passed immediately through an in-line cation exchange column which was placed in line with a conditioned graphitized carbon cartridge (300 mg) to recover glycosis.

A comparative glycan was recovered by conventional reductive beta-elimination in which the same amount of BSM was incubated in 0.05 M potassium hydroxide, 1.0M sodium borohydride for 16 hours at 45degreesC. The sample was desalted on graphitized carbon cartridge before analysis. The dominating oligosaccharides from both the test and comparative method were NeuAc/NeuGcalpha2-6GalNAc and GlcNAcbeta1-3 (NeuAc/NeuGcalpha2-6) GalNAc.

L48 ANSWER 5 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN

AN 1998-349729 [31] WPIX

DNC C1998-108132

TI Carob powder - comprises guaran prepared by flashing pressurised mixture of carob fragments and liquid **ammonia**, extracting fragments and separating husks from solution.

DC D13 D17 D21 F06 F09

```
KARSTENS, T; STEIN, A
TN
     (RHOD) RHODIA ACETOW AG; (RHON) RHONE-POULENC RHODIA AG; (RHOD) RHODIA
PA
    ACETOW GMBH
CYC
    82
                    A1 19980625 (199831)*
    DE 19654251
                                                      C08B037-00
PΙ
                    A1 19980702 (199832) GE
                                                      C08B037-14
                                                                     < - -
    WO 9828337
       RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA
           PT SD SE SZ UG ZW
        W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
            GH GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK
           MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US
           UZ VN YU ZW
                    A 19980717 (199848)
                                                                     <---
                                                      C08B037-14
     AU 9860911
                    A3 19990915 (199945)
                                                      C08B037-14
                                                                     <--
     CZ 9902261
                    A1 19991006 (199946) GE
                                                      C08B037-14
                                                                     <--
     EP 946599
        R: AT BE CH DE DK ES FI FR GB GR IT LI LT LV NL PT RO SE SI
                  A 19991103 (200011)
                                                      C08B037-14
     CN 1234040
                    B 20000120 (200015)
                                                      C08B037-14
                                                                     <---
     AU 715312
                    A 20000228 (200017)
    NZ 335980
                                                      C08B037-14
                                                                     <---
                        20000328 (200029)
                                                      C08B037-14
                                                                     <--
    BR 9713088
                    Α
                    W 20000627 (200036)
                                                      C08B037-14
                                                23
                                                                     <--
     JP 2000508018
                    A1 19990901 (200067)
                                                                     <--
    MX 9904231
                                                      C08B037-14
                    B1 20010228 (200113)
                                          GE
                                                      C08B037-14
     EP 946599
                                                                     <--
        R: AT BE CH DE DK ES FI FR GB GR IT LI LT LV NL PT RO SE SI
                   G 20010405 (200121)
                                                      C08B037-14
                                                                     <--
     DE 59703082
                        20001125 (200130)
                                                                     <--
     KR 2000069634
                    Α
                                                      C08B037-14
                                                                     <--
                    B1 20020219 (200221)
                                                      C08B037-00
     US 6348590
                                                                     <--
                    C 20040601 (200437) EN
                                                      C08B037-14
     CA 2274081
    DE 19654251 A1 DE 1996-1054251 19961223; WO 9828337 A1 WO 1997-EP7230
ADT
     19971222; AU 9860911 A AU 1998-60911 19971222; CZ 9902261 A3 WO
     1997-EP7230 19971222, CZ 1999-2261 19971222; EP 946599 A1 EP 1997-954940
     19971222, WO 1997-EP7230 19971222; CN 1234040 A CN 1997-198895 19971222;
     AU 715312 B AU 1998-60911 19971222; NZ 335980 A NZ 1997-335980 19971222,
     WO 1997-EP7230 19971222; BR 9713088 A BR 1997-13088 19971222, WO
     1997-EP7230 19971222; JP 2000508018 W WO 1997-EP7230 19971222, JP
     1998-528397 19971222; MX 9904231 A1 MX 1999-4231 19990506; EP 946599 B1 EP
     1997-954940 19971222, WO 1997-EP7230 19971222; DE 59703082 G DE
     1997-503082 19971222, EP 1997-954940 19971222, WO 1997-EP7230 19971222; KR
     2000069634 A WO 1997-EP7230 19971222, KR 1999-705643 19990621; US 6348590
     B1 WO 1997-EP7230 19971222, US 1999-297227 19990528; CA 2274081 C CA
     1997-2274081 19971222, WO 1997-EP7230 19971222
    AU 9860911 A Based on WO 9828337; CZ 9902261 A3 Based on WO 9828337; EP
     946599 Al Based on WO 9828337; AU 715312 B Previous Publ. AU 9860911,
     Based on WO 9828337; NZ 335980 A Based on WO 9828337; BR 9713088 A Based
     on WO 9828337; JP 2000508018 W Based on WO 9828337; EP 946599 B1 Based on
     WO 9828337; DE 59703082 G Based on EP 946599, Based on WO 9828337; KR
     2000069634 A Based on WO 9828337; US 6348590 B1 Based on WO 9828337; CA
     2274081 C Based on WO 9828337
PRAI DE 1996-19654251
                          19961223
     ICM C08B037-00; C08B037-14
         C07H001-00
     ICS
        19654251 A UPAB: 19980805
AΒ
     A method for isolating guaran from carob endosperm involves: (a) carob
     endosperm half-sections (carob fragments) are brought into contact with
     liquid ammonia at a pressure greater than 1 bar and a
     temperature of at least 25 deg. C, using sufficient ammonia to
     at least wet the carob fragment surfaces, and then the volume of the
     mixture is increased explosively by reducing the pressure by at least ca.
     5 bar; (b) the exploded material is treated with an extractant so that
     the guaran enters into solution whilst the endosperm husks remain
     undissolved; (c) the husks are separated; and (d) guaran is recovered
     from the guaran solution.
```

Guaran powder prepared by this method is also claimed.

FS

FΑ

MC

L48

AN

ΤI

DC

IN

PΑ

CYC

PΙ

ADT

USE - Carob flour, whose main component is guaran, is used as a stabiliser for ice-cream or certain soft cheeses, as a binder or thickener for sauces, as an additive for cosmetic products, for treating and sizing textiles, as a thickener for textile printing pastes or for increasing the strength of paper. ADVANTAGE - The liquid ammonia penetrates the carob endosperm husks and gets into the polysaccharide core to form intermolecular hydrogen bonds between polysaccharide molecules and then the explosion step evaporates the ammonia, splitting up the fragment surfaces and making the polysaccharide far more water soluble. Dwq.3/3CPI AB; GI CPI: D03-H01J; D03-H01Q; D08-B11; F03-E01; F03-F32; F05-A06C ANSWER 6 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN 1996-434840 [44] WPIX C1996-136501 DNC Polysaccharide activation to improve derivation reactivity - by sudden de-pressurisation of a polysaccharide/liquid ammonia mixture. KARSTENS, T; STEINMEIER, H; STIENMEIER, H (RHON) RHONE-POULENC RHODIA AG; (RHON) RHONE POULENC RHODIA AG; (RHOD) RHODIA ACETOW AG 72 DE 19611416 A1 19960926 (199644)* 13 C08B001-00 A1 19961003 (199645) GΕ 35 C08B001-00 WO 9630411 RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AU 9651481 Α 19961016 (199706) C08B001-00 ZA 9602370 Α 19961231 (199707) 32 C08B000-00 CZ 9703005 A3 19971217 (199807) C08B001-00 EP 817803 A1 19980114 (199807) GΕ C08B001-00 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE SK 9701285 A3 19980304 (199820) C08B001-00 JP 10505130 W 19980519 (199830) 31 C08B001-00 В 19980813 (199844) AU 695331 C08B001-00 B6 19981111 (199851) CZ 284387 C08B001-00 MX 9707309 A1 19971101 (199902) C08B001-00 A2 19990301 (199916) HU 9802337 C08B001-00 B1 19990616 (199928) EP 817803 GE C08B001-00 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE G 19990722 (199935) C08B001-00 DE 59602248 Α US 5939544 19990817 (199939) C08B001-00 ES 2135221 T3 19991016 (199950) C08B001-00 KR 98703294 Α 19981015 (199950) C08B001-00 В 19991029 (200001) C08B001-00 RO 115053 Α BR 9607992 19991130 (200014) C08B001-00 B1 20000501 (200128) C08B001-00 KR 254840 С 20011002 (200161) EN C08B001-00 CA 2214245 20001205 (200220) MX 199969 В C08B001-00 Α 19980422 (200222) C08B001-00 CN 1179781 JP 2002161101 20020604 (200239) 12 C08B001-00 Α B2 20030324 (200323) 12 C08B001-00 JP 3390015 DE 19611416 A1 DE 1996-1011416 19960322; WO 9630411 A1 WO 1996-EP1274 19960322; AU 9651481 A AU 1996-51481 19960322; ZA 9602370 A ZA 1996-2370 19960325; CZ 9703005 A3 WO 1996-EP1274 19960322, CZ 1997-3005 19960322; EP 817803 A1 EP 1996-908120 19960322, WO 1996-EP1274 19960322; SK 9701285 A3 WO 1996-EP1274 19960322, SK 1997-1285 19960322; JP 10505130 W JP

1996-528906 19960322, WO 1996-EP1274 19960322; AU 695331 B AU 1996-51481

```
19960322; CZ 284387 B6 WO 1996-EP1274 19960322, CZ 1997-3005 19960322; MX
     9707309 A1 MX 1997-7309 19970924; HU 9802337 A2 WO 1996-EP1274 19960322,
    HU 1998-2337 19960322; EP 817803 B1 EP 1996-908120 19960322, WO
     1996-EP1274 19960322; DE 59602248 G DE 1996-502248 19960322, EP
     1996-908120 19960322, WO 1996-EP1274 19960322; US 5939544 A WO 1996-EP1274
     19960322, US 1997-913782 19971106; ES 2135221 T3 EP 1996-908120 19960322;
     KR 98703294 A WO 1996-EP1274 19960322, KR 1997-706698 19970925; RO 115053
    B WO 1996-EP1274 19960322, RO 1997-1782 19960322; BR 9607992 A BR
     1996-7992 19960322, WO 1996-EP1274 19960322; KR 254840 B1 WO 1996-EP1274
     19960322, KR 1997-706698 19970925; CA 2214245 C CA 1996-2214245 19960322,
    WO 1996-EP1274 19960322; MX 199969 B MX 1997-7309 19970924; CN 1179781 A
     CN 1996-192823 19960322; JP 2002161101 A Div ex JP 1996-528906 19960322,
     JP 2001-343847 19960322; JP 3390015 B2 JP 1996-528906 19960322, WO
     1996-EP1274 19960322
    AU 9651481 A Based on WO 9630411; CZ 9703005 A3 Based on WO 9630411; EP
FDT
     817803 Al Based on WO 9630411; JP 10505130 W Based on WO 9630411; AU
     695331 B Previous Publ. AU 9651481, Based on WO 9630411; CZ 284387 B6
     Previous Publ. CZ 9703005, Based on WO 9630411; HU 9802337 A2 Based on WO
     9630411; EP 817803 B1 Based on WO 9630411; DE 59602248 G Based on EP
     817803, Based on WO 9630411; US 5939544 A Based on WO 9630411; ES 2135221
     T3 Based on EP 817803; KR 98703294 A Based on WO 9630411; RO 115053 B
     Based on WO 9630411; BR 9607992 A Based on WO 9630411; CA 2214245 C Based
     on WO 9630411; JP 3390015 B2 Previous Publ. JP 10505130, Based on WO
     9630411
PRAI DE 1995-19511061
                          19950325
    DE 4329937; EP 77287
     ICM C08B000-00; C08B001-00
         C08B001-02; C08B001-06; C08B030-00; C08B030-02; C08B037-00;
          C08B037-08; C08L000-00; D01F002-02
        19611416 A UPAB: 19961104
     Activation of polysaccharides is effected by (i) contacting the
     polysaccharide material with liq.NH3 at superatmos. pressure
     (pref. 5-46, especially 25-30) bar and above 25 (pref. 25-85, especially
55-65) deq.C.,
     with the amount of NH3 being sufficient to wet the polysaccharide
     surface; and then (ii) releasing the pressure by around 5 bar so that the
     volume of the system increases in explosive fashion (pref. in less than 1
         ADVANTAGE - Polysaccharide such as cellulose galactomannan, guar gum,
     starch or chitin can be modified to have increased reactivity in
     derivation reactions such as acylation, alkylation, silylation,
     xanthogenation or carbamoylation.
     Dwg.3/3
     CPI
     AB; GI
     CPI: A03-A; A10-E01; F01-D01; F01-D06; F01-D10
    ANSWER 7 OF 7 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
     1993-128045 [16]
                       WPIX
     1991-052945 [08]
    C1993-056852
     N-linked peptide glyco-conjugate(s) preparation - by reacting
     oligosaccharide(s) with ammonium bi carbonate to maintain
     beta-anomeric configuration, and avoid separation of anomers.
     DWEK, R A; MANGER, I D; RADEMACHER, T W; WONG, S Y C; WONG, S
     (MONS) MONSANTO CO; (OXFO-N) OXFORD GLYCOSYSTEMS LTD
                     A1 19930421 (199316)* EN
                                                      A61K047-48
     EP 538230
                                                50
        R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
                                                      C07H005-04
                    A 19930518 (199321)
                                                33
     US 5212298
                       19930416 (199326)
                                                      C07K009-00
     CA 2080502
                    Α
                    A 19930831 (199339)
                                                31
                                                      C07K015-14
```

AB

FS

FA

MC

L48 AN

CR DNC

DC

TN

PΑ CYC

PΙ

JP 05222099

US 5280113 A 19940118 (199404) 33 C07H005-04

ADT EP 538230 A1 EP 1992-870165 19921014; US 5212298 A CIP of US 1989-394691 19890816, US 1991-776911 19911015; CA 2080502 A CA 1992-2080502 19921014; JP 05222099 A JP 1992-275945 19921014; US 5280113 A CIP of US 1989-394691 19890816, CIP of US 1991-776911 19911015, US 1992-926786 19920811

FDT US 5280113 A CIP of US 5212298

PRAI US 1992-926786 19920811; US 1991-776911 19911015; US 1989-394691 19890816

REP 1.Jnl.Ref; EP 413675

IC ICM A61K047-48; C07H005-04; C07K009-00; C07K015-14 ICS C07K001-10; C07K003-08; C08B037-00; C12Q001-00

AB EP 538230 A UPAB: 19951114

Production of a synthetic N-linked glycoconjugate of a peptide (PGC) under conditions to maintain the beta-anomeric configuration directly, comprising (a) reacting a complex, unprotected oligosaccharide (OS), up to 9-mer, with saturated NH4HCO3 at pH 8-8.5 to form an unprotected beta-glycosylamine derivative of the OS; and (b) reacting with a peptide having 5- about 25 amino acid residues and an activated COOH gp. capable of forming a beta-glycosylamine linked glycoconjugate of the peptide and animated OS; is new.

USE/ADVANTAGE - The narrow pH limits ensure maximum mutarotation of the OS in favour of the beta-nucleophile and avoiding beta-elimination. The prods. possess a peptide linkage to the OS through an amide gp., as in glycoproteins with an aspargine link to the reducing terminal. Conjugation to OS in this way increases the stability and half life of small peptide hormones, and improves recognition of peptide vaccines. The method can be used to prepare the bioactive hormones known as atriopept Dwg.0/17

Dwg.0/17

FS CPI

FA AB; DCN

ABEQ US 5212298 A UPAB: 19931114

Prodn. of synthetic N-linked glyco-conjugates of oligosaccharides (I) is carried out under conditions which maintain the closed ring structure of the terminal monosaccharide of (I) in the beta-anomeric configuration.

(I) are reacted in satd. NH4HCO3 at pH 8-8.5 to form a beta-glycosylamine deriv. This is then haloacetylated in aq. phase to form the corresp. 1-N-haloacetamido deriv. without selective crystallisation in an organic medium. The prod. is converted by ammonolysis to a 1-N-glycyl-beta-glycosylamine deriv. This is then reacted with a substrate which can form a linked glyco-conjugated with it.

The substrate is pref. a fluorophone, lipid, peptide, protein or plastic and is esp. fluorescein isothiocyanate, tripalmitoyl-S-glycyrylcysteine, atriopeptin, gentiobiose conjugated to serum albumin or polystyrene.

USE - For clinical research, pharmacology and diagnostic medicine. Dwg.0/17

ABEQ US 5280113 A UPAB: 19940307

Prepn. of N-linked peptide glyco conjugates in which the beta-anomeric configuration is retained, comprises reaction of a complex, non-protected oligosaccharide (having up to 9 saccharide units) with satd. aq. NH4HCO3 soln. at pH about 8.0-8.5; then reaction of the resulting unprotected beta-glycosylamine deriv. with a peptide (contg. 5-25 aminoacid units) having an activated COOH function to form the conjugate, in a mixt. of DMF (about 85 vol) and DMSO (about 50 vol.). Pref. peptides are pentapeptides having a formula Met-Asp-Pro-X-Phe in which X is Thr or Ser, or Ala-Glu-Ala-Thr-Phe; and atriopeptin.

USE - The prods. are reagents for analysis or diagnosis, and also intermediates for potential therapeutics, diagnostic reagents, etc.. Dwg.0/17

(FILE 'HOME' ENTERED AT 13:23:07 ON 10 NOV 2004) SET COST OFF

```
FILE 'WPIX' ENTERED AT 13:23:20 ON 10 NOV 2004
           1910 S C12P019-04/IPC
L1
           8150 S C08B037/IPC
L2
           1773 S (B04-C02X OR C04-C02X)/MC
L3
          10754 S L1-L3
L4
             28 S L4 AND (B05-C01 OR C05-C01)/MC
L5
                E AMMONIA/DCN
                E E3+ALL
          18689 S E2 OR 1713/DRN
L6
                E AMMONIA/DCN
                E E31+ALL
           1808 S E2 OR 1304/DRN
L7
                E AMMONIA/DCN
                E E78+ALL
           5377 S E2 OR 1534/DRN
L8
L9
             47 S L4 AND L6-L8
L10
             67 S L5, L9
              1 S L10 AND C12P021-06/IPC
L11
              7 S L10 AND (B04-N04? OR C04-N04? OR B04-C01? OR C04-C01?)/MC
L12
              3 S L10 AND S03-E14H?/MC
L13
              4 S L10 AND (B04-N06 OR C04-N06 OR B04-B04A OR C04-B04A)/MC
L14
              8 S L11-L14
L15
              2 S L15 AND (AMMON? HYDROXIDE OR AMMON? CARBONATE)/BIX
L16
              1 S L16 NOT LIPID/TI
L17
              6 S L10 AND (AMMON? HYDROXIDE OR AMMON? CARBONATE)/BIX NOT L16
L18
                SEL DN AN 3
              1 S L18 AND E1-E2
L19
L20
              2 S L17, L19
            979 S L4 AND (S03-E14H? OR B04-N04? OR C04-N04? OR B04-C01? OR C04-
L21
L22
             16 S L3 AND C12P021-06/IPC
L23
            978 S L21, L22 NOT L15
              0 S L23 AND L6-L8
L24
              0 S L23 AND L5
L25
             58 S L23 AND ?AMMONI?/BIX
L26
             59 S L10 NOT L15
L27
            117 S L26, L27
L28
                SEL DN AN 31 65 73
L29
              3 S E3-E8
L30
              4 S L20, L29
                E HUANG Y/AU
           2527 S E3-E24
L31
                E MECHREF Y/AU
L32
              5 S E3, E4
                E NOVOTNY M/AU
L33
             60 S E3-E7
           2584 S L31-L33
L34
L35
              8 S L34 AND L4
                SEL DN AN 1 5-8
              3 S L35 NOT E1-E12
L36
L37
              6 S L30, L36
L38
              6 S L37 AND L1-L37
            852 S L4 AND (NH4? OR NH3? OR ?AMMONI?)/BIX
L39
            868 S L10, L39
L40
              9 S L40 AND (?GLYCOPROTEIN? OR ?GLYCO PROTEIN?)/BIX
L41
L42
              1 S L40 AND C12P021-06/IPC
             53 S L40 AND (B04-N04 OR C04-N04 OR B04-C01 OR C04-C01)/MC
L43
             12 S L40 AND (B04-B04A OR C04-B04A)/MC
L44
             67 S L41-L44
L45
             18 S L45 NOT L28
L46
```

SEL DN AN 1 3 11 L47 3 S E13-E20 AND L46 L48 7 S L38,L47 AND L1-L47

FILE 'WPIX' ENTERED AT 14:09:36 ON 10 NOV 2004

=>